A Phase 1 interventional study of KH176 and placebo in MELAS, LHON and Leigh Syndrome, sponsored by Khondrion BV. Completed at 1 site in Belgium. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-10-18.
Sponsored by Khondrion BV · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Mitochondrial Diseases are rare progressive, multi-system, often early fatal disorders affecting both children and adults. KH176 is a novel chemical entity currently under development for the treatment of inherited mitochondrial diseases, including MELAS (Mitochondrial Encephalomyopathy, Lactic acidosis, and Stroke-like episodes), Leigh's Disease and Leber's Hereditary Optic Neuropathy (LHON). KH176 is a potent intracellular redox modulating agent targeting the reactive oxygen species which are important in the pathogenesis of disorders of mitochondrial oxidative phosphorylation. After demonstrating a favourable safety profile in the pre-clinical testing, the safety, tolerability and pharmacokinetic and pharmacodynamic characteristics of the compound will now be evaluated in healthy male subjects in this trial
37 studies on the registry are indexed under MELAS Syndrome; 8 are open to participants now.
This study's enrollment of 32 is above the median of 24 across 29 interventional studies indexed under MELAS Syndrome.
Browse MELAS Syndrome studies →Khondrion BV is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
2 alternating groups receiving escalating single doses of active/placebo
Drug: KH176 · Drug: placebo
3 multiple escalating groups, receiving active/placebo
Drug: KH176 · Drug: placebo
SAD: Change From Baseline in ECG Results by Timepoint: Corrected QT Interval According to Fridericia's Formula (QTcF)
The baseline ECG recording consists of a triplicate recording (3 recordings of a least 3 complexes within a 5 minute window) prior to dosing on Day 1. For the evaluation of the corrected QT intervals the average of the 3 recordings will be taken as baseline. Other ECG recordings will be singlet (one recording of at least 3 complexes) prior to dosing. QTcF is calculated as the quotient between the QT interval in milliseconds and the cube root of the RR interval in seconds, according to Fridericia's formula.
Time frame: Baseline, 1, 2, 4, 6, 8, 12, 24 hours, 7 day follow up
Pharmacodynamics of KH176
Change from baseline in biochemistry related to Oxidative Phosphorylation (OXPHOS) (glutathione, lactate); MAD group
Time frame: Day 1, day 7
Relationship to Study Drug and Severity of Treatment-emergent Adverse Events
Time frame: 4 months
Change From Baseline in Hematology Laboratory Test Results by Timepoint: Red Blood Cell Count. SAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline (pre-dose Day 1), 24h post dose, FU (7 days after last dosing)
Change From Baseline in Hematology Laboratory Test Results by Timepoint: Erythrocyte Sedimentation Rate (SAD Group)
Time frame: Baseline (pre-dose Day1), 24h post dose, FU (7 days after last dosing)
Change From Baseline in Hematology Laboratory Test Results by Timepoint: Erythrocyte Sedimentation Rate MAD Group
Time frame: Baseline (pre-dose Day 1), Day 3, Day 8, FU (7 days after last dosing)
Change From Baseline in Hematology Laboratory Test Results by Timepoint: Hematocrit SAD Group
Hematocrit is a measure of the ratio of red blood cells (RBCs) in the blood by volume. Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline (pre-dose Day 1), 24 h postdose, FU (7 days after last dosing)
Change From Baseline in Hematology Laboratory Test Results by Timepoint: Mean Corpuscular Haemoglobin. SAD
Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline (pre-dose Day 1), 24 h post dose, FU (7 days after last dosing)
Change From Baseline in Hematology Laboratory Test Results by Timepoint: Mean Corpuscular Hemoglobin Concentration - SAD
Erythrocyte mean corpuscular hemoglobin concentration (MCHC) is a measure of the average concentration of hemoglobin per red blood cell. Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline (pre-dose Day 1), 24 h post dose, FU (7 days after last dosing)
Change From Baseline in Hematology Laboratory Test Results by Timepoint: Mean Corpuscular Volume - SAD
Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline (pre-dose Day 1), 24 h post dose, FU (7 days after last dosing)
MAD: Change From Baseline in ECG Results by Time Point: QTcF
The baseline ECG recording consists of a triplicate recording (3 recordings of a least 3 complexes within a 5 minute window) prior to dosing on Day 1. For the evaluation of the corrected QT intervals the average of the 3 recordings will be taken as baseline. Other ECG recordings will be singlet (one recording of at least 3 complexes) prior to dosing, or around the expected Cmax on Day 1 or 7 for the multiple-dose part. QTcF is calculated as the quotient between the QT interval in milliseconds and the cube root of the RR interval in seconds, according to Fridericia's formula.
Time frame: Baseline, Day1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7
Change From Baseline in Hematology Laboratory Test Results by Timepoint: White Blood Cell Count. SAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline (pre-dose Day 1), 24h post dose, FU (7 days after last dosing)
Change From Baseline in Hematology Laboratory Test Results by Timepoint: Lymphocytes. SAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)
Change From Baseline in Hematology Laboratory Test Results by Timepoint: Neutrophils. SAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline (pre-dose Day 1), 24h post dose, FU (7 days after last dosing)
Change From Baseline in Hematology Laboratory Test Results by Timepoint: Hematocrit MAD Group
Hematocrit is a measure of the ratio of red blood cells (RBCs) in the blood by volume. Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value
Time frame: Baseline (pre-dose Day 1), Day 3, Day 8, FU (7 days post dose)
Change From Baseline in Hematology Laboratory Test Results by Timepoint: Eosinophils. SAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline (pre-dose Day 1), 24h post dose, FU (7 days after last dosing)
Change From Baseline in Hematology Laboratory Test Results by Timepoint: Thrombocytes. SAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline (pre-dose Day 1), 24h, FU (7 days post-dose)
Change From Baseline in Hematology Laboratory Test Results by Timepoint: Basophils. SAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value ateach timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline (pre-dose Day 1), 24h post dose, FU (7 days post-dose)
Change From Baseline in Hematology Laboratory Test Results by Timepoint: Monocytes. SAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline (pre-dose Day 1), 24h post dose, FU (7 days post-dose)
Change From Baseline in Hematology Laboratory Test Results by Timepoint: Mean Corpuscular Volume. MAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline (pre-dose Day 1), Day 3, Day 8, FU (7 days post dose)
Change From Baseline in Hematology Laboratory Test Results by Timepoint: Hemoglobin. MAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline (pre-dose Day 1), Day 3, Day 8, FU (7 days post dose)
Change From Baseline in Hematology Laboratory Test Results by Timepoint: White Blood Cell Count. MAD
Blood samples were collected from participants at the indicated time points for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each time point are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline (pre-dose Day 1), Day 3, Day 8, FU (7 days post dose)
Change From Baseline in Hematology Laboratory Test Results by Timepoint: Neutrophils. MAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline (pre-dose Day 1), Day 3, Day 8, FU (7 days post dose)
Change From Baseline in Hematology Laboratory Test Results by Timepoint: Mean Corpuscular Haemoglobin Concentration. MAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline (pre-dose Day 1), Day 3, Day 8, FU (7 days post dose)
Change From Baseline in Hematology Laboratory Test Results by Timepoint: Lymphocytes. MAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline (pre-dose Day 1), Day 3, Day 8, FU (7 days post dose)
Change From Baseline in Hematology Laboratory Test Results by Timepoint: Mean Corpuscular Hemoglobin. MAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline (pre-dose Day 1), Day 3, Day 8, FU (7 days post dose)
Change From Baseline in Hematology Laboratory Test Results by Timepoint: Red Blood Cell Count. MAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline (pre-dose Day 1), Day 3, Day 8, FU (7 days post dose)
Change From Baseline in Hematology Laboratory Test Results by Timepoint: Eosinophils. MAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline (pre-dose Day 1), Day 3, Day 8, FU (7 days post dose)
Change From Baseline in Hematology Laboratory Test Results by Timepoint: Monocytes. MAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline (pre-dose Day 1), Day 3, Day 8, FU (7 days post dose)
Change From Baseline in Hematology Laboratory Test Results by Timepoint: Thrombocytes. MAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline (pre-dose Day 1), Day 3, Day 8, FU (7 days post dose)
Change From Baseline in Hematology Laboratory Test Results by Timepoint: Basophils. MAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline (pre-dose Day 1), Day 3, Day 8, FU (7 days post dose)
Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Aspartate Aminotransferase. SAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)
Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Total Protein. SAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)
Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Gamma-GT. SAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value
Time frame: Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)
Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Alkaline Phosphatase. SAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)
Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Creatinine. SAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)
Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Chloride. SAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)
Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Total Bilirubin. SAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)
Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Alanine Aminotransferase. SAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)
Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Creatinine Kinase. SAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)
Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Urea. SAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)
Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Sodium. SAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)
Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Potassium. SAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)
Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Phosphate. SAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)
Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Calcium (Corrected for Albumin). SAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)
Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Uric Acid. SAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)
Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Triiodothyronine (T3). SAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)
Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Lipase. SAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)
Change From Baseline in Chemistry Laboratory Test Results by Timepoint: (Fasting) Glucose. SAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)
Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Human Serum Albumin. SAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)
Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Cholesterol. SAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)
Change From Baseline in Chemistry Laboratory Test Results by Timepoint: High Density Lipoproteins. SAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)
Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Triglycerides. SAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)
Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Low Density Lipoproteins. SAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)
Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Bicarbonate. SAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)
Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Thyroid-stimulating Hormone. SAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)
Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Thyroxine (T4). SAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)
Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Lactate. SAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)
Change From Baseline in Chemistry Laboratory Test Results by Time Point: Total Protein. MAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline (pre-dose Day1), Day 3, Day 8, FU (one week after last dosing)
Change From Baseline in Chemistry Laboratory Test Results by Time Point: Alkaline Phosphatase. MAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline, Day 3, Day 8, FU (one week after last dosing)
Change From Baseline in Chemistry Laboratory Test Results by Time Point: Aspartate Aminotransferase. MAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline, Day 3, Day 8, FU (one week after last dosing)
Change From Baseline in Chemistry Laboratory Test Results by Time Point: Creatine Kinase. MAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline, Day 3, Day 8, FU (one week after last dosing)
Change From Baseline in Chemistry Laboratory Test Results by Time Point: Gamma GT. MAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline, Day 3, Day 8, FU (one week after last dosing)
Change From Baseline in Chemistry Laboratory Test Results by Time Point: Total Bilirubin. MAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline, Day 3, Day 8, FU (one week after last dosing)
Change From Baseline in Chemistry Laboratory Test Results by Time Point: Urea. MAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline, Day 3, Day 8, FU (one week after last dosing)
Change From Baseline in Chemistry Laboratory Test Results by Time Point: Creatinine. MAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline, Day 3, Day 8, FU (one week after last dosing)
Change From Baseline in Chemistry Laboratory Test Results by Time Point: Sodium. MAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline, Day 3, Day 8, FU (one week after last dosing)
Change From Baseline in Chemistry Laboratory Test Results by Time Point: Potassium. MAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline, Day 3, Day 8, FU (one week after last dosing)
Change From Baseline in Chemistry Laboratory Test Results by Time Point: Chloride. MAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline, Day 3, Day 8, FU (one week after last dosing)
Change From Baseline in Chemistry Laboratory Test Results by Time Point: Calcium (Corrected for Albumin). MAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline, Day 3, Day 8, FU (one week after last dosing)
Change From Baseline in Chemistry Laboratory Test Results by Time Point: Uric Acid. MAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline, Day 3, Day 8, FU (one week after last dosing)
Change From Baseline in Chemistry Laboratory Test Results by Time Point: Lipase. MAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline, Day 3, Day 8, FU (one week after last dosing)
Change From Baseline in Chemistry Laboratory Test Results by Time Point: Alanine Aminotransferase. MAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline, Day 3, Day 8, FU (one week after last dosing)
Change From Baseline in Chemistry Laboratory Test Results by Time Point: Phosphate. MAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline, Day 3, Day 8, FU (one week after last dosing)
Change From Baseline in Chemistry Laboratory Test Results by Time Point: Human Serum Albumin. MAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline, Day 3, Day 8, FU (one week after last dosing)
Change From Baseline in Chemistry Laboratory Test Results by Time Point: Fasting Glucose. MAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline, Day 3, Day 8, FU (one week after last dosing)
Change From Baseline in Chemistry Laboratory Test Results by Time Point: Cholesterol. MAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline, Day 3, Day 8, FU (one week after last dosing)
Change From Baseline in Chemistry Laboratory Test Results by Time Point: Triglycerides. MAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline, Day 3, Day 8, FU (one week after last dosing)
Change From Baseline in Chemistry Laboratory Test Results by Time Point: Low Density Lipoproteins. MAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline, Day 3, Day 8, FU (one week after last dosing)
Change From Baseline in Chemistry Laboratory Test Results by Time Point: High Density Lipoproteins. MAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline, Day 3, Day 8, FU (one week after last dosing)
Change From Baseline in Chemistry Laboratory Test Results by Time Point: Thyroid-stimulating Hormone. MAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline, Day 3, Day 8, FU (one week after last dosing)
Change From Baseline in Chemistry Laboratory Test Results by Time Point: Trilodothyronine (T3). MAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline, Day 3, Day 8, FU (one week after last dosing)
Change From Baseline in Chemistry Laboratory Test Results by Time Point: Thyroxine (T4). MAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline, Day 3, Day 8, FU (one week after last dosing)
Change From Baseline in Chemistry Laboratory Test Results by Time Point: Bicarbonate. MAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline, Day 3, Day 8, FU (one week after last dosing)
Change From Baseline in Chemistry Laboratory Test Results by Time Point: Lactate. MAD Group
Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
Time frame: Baseline, Day 3, Day 8, FU (one week after last dosing)
Phospholipidosis
Change from Day 1 to Day 7 in di-docosahexaenoyl (22:6)-bis(monoacylglycerol) phosphate (di-22:6-BMP) and normalized di-22:6-BMP (urine) - MAD
Time frame: Day 1, Day 7
MAD: Change From Baseline in ECG Results by Time Point: Corrected QT Interval According to Barret's Formaula (QTcB)
The baseline ECG recording consists of a triplicate recording (3 recordings of a least 3 complexes within a 5 minute window) prior to dosing on Day 1. For the evaluation the average of the 3 recordings will be taken as baseline. Other ECG recordings will be singlet (one recording of at least 3 complexes) prior to dosing, or around the expected Cmax on Day 1 or 7 for the multiple- dose part.
Time frame: Baseline (pre-dose Day 1), Day1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Follow-up
MAD: Change From Baseline in ECG Results by Time Point: P Wave-Q Wave Interval (PQ Interval)
The baseline ECG recording consists of a triplicate recording (3 recordings of a least 3 complexes within a 5 minute window) prior to dosing on Day 1. For the evaluation of the PQ interval the average of the 3 recordings will be taken as baseline.
Time frame: Baseline (pre-dose Day 1), Day1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Follow-up
MAD: Change From Baseline in ECG Results by Time Point: the Interval That Denotes Depolarization of the Ventricles, Between the Beginning of the Q Wave and the End of the S Wave (QRS Interval)
The baseline ECG recording consists of a triplicate recording (3 recordings of a least 3 complexes within a 5 minute window) prior to dosing on Day 1. For the evaluation the average of the 3 recordings will be taken as baseline. Other ECG recordings will be singlet (one recording of at least 3 complexes) prior to dosing, or around the expected Cmax on Day 1 or 7 for the multiple- dose part.
Time frame: Baseline (pre-dose Day 1), Day1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Follow-up
MAD: Change From Baseline in ECG Results by Time Point: QT Interval
The baseline ECG recording consists of a triplicate recording (3 recordings of a least 3 complexes within a 5 minute window) prior to dosing on Day 1. For the evaluation the average of the 3 recordings will be taken as baseline. Other ECG recordings will be singlet (one recording of at least 3 complexes) prior to dosing, or around the expected Cmax on Day 1 or 7 for the multiple- dose part.
Time frame: Baseline (pre-dose Day 1), Day1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Follow-up
SAD: Change From Baseline in ECG Results by Time Point: PQ Interval
The baseline ECG recording consists of a triplicate recording (3 recordings of a least 3 complexes within a 5 minute window) prior to dosing on Day 1. For the evaluation the average of the 3 recordings will be taken as baseline.
Time frame: Pre-dose, Day 1, Day 7
SAD: Change From Baseline in ECG Results by Time Point: QRS Interval
The baseline ECG recording consists of a triplicate recording (3 recordings of a least 3 complexes within a 5 minute window) prior to dosing on Day 1. For the evaluation the average of the 3 recordings will be taken as baseline.
Time frame: Pre-dose, Day 1, Day 7
SAD: Change From Baseline in ECG Results by Time Point: QT Interval
The baseline ECG recording consists of a triplicate recording (3 recordings of a least 3 complexes within a 5 minute window) prior to dosing on Day 1. For the evaluation the average of the 3 recordings will be taken as baseline.
Time frame: Pre-dose, Day 1, Day 7
SAD: Change From Baseline in ECG Results by Time Point: QTcB Interval
The baseline ECG recording consists of a triplicate recording (3 recordings of a least 3 complexes within a 5 minute window) prior to dosing on Day 1. For the evaluation the average of the 3 recordings will be taken as baseline.
Time frame: Pre-dose, Day1, Day 7
Terminal Elimination Half-life (T1/2) of KH176 Over 24 Hours: SAD
Plasma concentrations of KH176 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food), 300mg, 800mg, 2000mg b.i.d.
Time frame: Pre-dose (5 min before dosing) and 0.5, 1, 1.5, 2, 3, 6, 8, 12, and 24 hours post-dose
Terminal Elimination Half-life (T1/2) of KH183: SAD
Plasma concentrations of KH183 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food) , 300mg, 800mg, 2000mg b.i.d.
Time frame: Pre-dose (5 min before dosing) and 0.5, 1, 1.5, 2, 3, 6, 8, 12, and 24 hours post-dose
Maximum Concentration (Cmax) of KH176: SAD Group
Plasma concentrations of KH176 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food), 300mg, 800mg, 2000mg b.i.d.
Time frame: Pre-dose (5 min before dosing) and 0.5, 1, 1.5, 2, 3, 6, 8, 12, and 24 hours post-dose
Maximum Concentration (Cmax) of KH183 Over 24 Hours: SAD
Plasma concentrations of KH183 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food) , 300mg, 800mg, 2000mg b.i.d.
Time frame: Pre-dose (5 min before dosing) and 0.5, 1, 1.5, 2, 3, 6, 8, 12, and 24 hours post-dose
Maximum Concentration (Cmax) of KH183 (Active Metabolite of KH176): MAD Group
Plasma concentrations of KH183 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.: Cmax was obtained directly from the concentration-time data.
Time frame: Predose at Day 1, 2, 4, 7, and post-dose at Day 1 and Day 7 at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours
Maximum Concentration (Cmax) of KH176: MAD
Plasma concentrations of KH176 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.
Time frame: pre-dose at Day 1, 2, 4, 7, and post-dose at Day 1 and Day 7 at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours
Time to Maximum Concentration (Tmax) of KH176 Over 24 Hours: SAD
Plasma concentrations of KH176 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food), 300mg, 800mg, 2000mg b.i.d.
Time frame: Pre-dose (5 min before dosing) and 0.5, 1, 1.5, 2, 3, 6, 8, 12, and 24 hours post-dose
Time to Reach Peak Plasma Concentration (Tmax) of KH183: SAD
Plasma concentrations of KH183 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food), 300mg, 800mg, 2000mg b.i.d.
Time frame: Pre-dose (5 min before dosing) and 0.5, 1, 1.5, 2, 3, 6, 8, 12, and 24 hours post-dose
Time to Maximum Concentration (Tmax) of KH176 at Day 1, Day 7: MAD Group
Plasma concentrations of KH176 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.
Time frame: pre-dose at Day 1, 2, 4, 7, and post-dose at Day 1 and Day 7 at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours
Time to Maximum Concentration (Tmax) of KH183 (Active Metabolite of KH176): MAD Group
Plasma concentrations of KH183 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.. tmax was obtained directly from the concentration-time data.
Time frame: Predose at Day 1, 2, 4, 7, and post-dose at Day 1 and Day 7 at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours
Accumulation Factor (Racc) of KH176 Over 7 Days: MAD Group
Plasma concentrations of KH176 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.. Racc was calculated as follows: AUCtau day 7/ AUCtau day 1.
Time frame: Pre-dose at Day 1, 2, 4, 7, and post-dose at Day 1 and Day 7 at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours
Accumulation Factor (Racc) of KH183 (Active Metabolite of KH176): MAD Group
Plasma concentrations of KH183 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.: Accumulation factor was calculated as follows: AUCtau day 7/ AUCtau day 1.
Time frame: Predose at Day 1, 2, 4, 7, and post-dose at Day 1 and Day 7 at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours
Area Under the Plasma Concentration Versus Time Curve (AUClast) of KH183: SAD Group
Plasma concentrations of KH183 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food) , 300mg, 800mg, 2000mg b.i.d.
Time frame: Pre-dose (5 min before dosing) and 0.5, 1, 1.5, 2, 3, 6, 8, 12, and 24 hours post-dose
Area Under the Plasma Concentration Versus Time Curve (AUClast) of KH176: SAD Group
Plasma concentrations of KH176 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food), 300mg, 800mg, 2000mg b.i.d.
Time frame: pre-dose (5 min before dosing) and 0.5, 1, 1.5, 2, 3, 6, 8, 12, and 24 hours post-dose
Area Under the Plasma Concentration-time Curve (AUCtau) of KH176: MAD Group:
Plasma concentrations of KH176 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.
Time frame: Pre-dose at Day 1, 2, 4, 7, and post-dose at Day 1 and Day 7 at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours
Area Under the Plasma Concentration-time Curve During a Dose Interval (AUCtau) of KH183 (Active Metabolite of KH176): MAD Group
Plasma concentrations of KH183 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.
Time frame: Predose at Day 1, 2, 4, 7, and post-dose at Day 1 and Day 7 at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours
Area Under the Plasma Concentration-time Curve From Time Zero Until Infinity (AUCl0-inf) of KH183: SAD
Plasma concentrations of KH183 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food) , 300mg, 800mg, 2000mg b.i.d.
Time frame: Pre-dose (5 min before dosing) and 0.5, 1, 1.5, 2, 3, 6, 8, 12, and 24 hours post-dose
Area Under the Plasma Concentration-time Curve From Time Zero Until Infinity (AUCl0-inf) of KH176: SAD
Plasma concentrations of KH176 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food) , 300mg, 800mg, 2000mg b.i.d.
Time frame: Pre-dose (5 min before dosing) and 0.5, 1, 1.5, 2, 3, 6, 8, 12, and 24 hours post-dose
KH176: Percentage of Administered Dose Excreted in Urine: SAD
Urine concentrations of KH176 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food), 300mg, 800mg, 2000mg b.i.d.
Time frame: 24 hours post-dose
KH183: Percentage of Administered Dose Excreted in Urine: SAD
Urine concentrations of KH176 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food), 300mg, 800mg, 2000mg b.i.d.
Time frame: 24 hours post-dose
KH176 + KH183: Percentage of Administered Dose Excreted in Urine: SAD
Urine concentrations of KH176 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food), 300mg, 800mg, 2000mg b.i.d.
Time frame: 24 hours post-dose
KH176: Percentage of Administered Dose Excreted in Urine: MAD
Urine concentrations of KH176 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.
Time frame: Day 7 post dose
KH183: Percentage of Administered Dose Excreted in Urine: MAD
Urine concentrations of KH183 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.
Time frame: Post dose Day 7
KH173 + KH183: Percentage of Administered Dose Excreted in Urine: MAD
Urine concentrations of KH176 and KH183 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.
Time frame: Day 7 Post dose
All studies were conducted at the Drug Research Unit Ghent. Participants agreed to stay in the Drug Research Unit during the first 24 h after dosing (SAD) and during Day 8 (MAD).
| Milestone | Single Ascending Group I | Single Ascending Group II | Multiple Ascending Group III | Multiple Ascending Group IV | Multiple Ascending Group V | Placebo |
|---|---|---|---|---|---|---|
| Started | 7 | 7 | 4 | 4 | 4 | 6 |
| Completed | 6 | 6 | 4 | 4 | 4 | 6 |
| Not completed | 1 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 | 0 | 0 | 0 | 0 |
The baseline ECG recording consists of a triplicate recording (3 recordings of a least 3 complexes within a 5 minute window) prior to dosing on Day 1. For the evaluation of the corrected QT intervals the average of the 3 recordings will be taken as baseline. Other ECG recordings will be singlet (one recording of at least 3 complexes) prior to dosing. QTcF is calculated as the quotient between the QT interval in milliseconds and the cube root of the RR interval in seconds, according to Fridericia's formula.
| msec | Group I Placebo | Group II Placebo | SAD Group I 10mg | SAD Group II 30mg | SAD Group I 100mg | SAD Group II 300mg | SAD Group I 800mg | SAD Group II 2000mg | Group I Placebo + Food | Group I 100mg + Food |
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (Pre-dose Day 1) | 386.2 ± 17.2 | 395.0 ± 9.8 | 385.8 ± 14.8 | 399.3 ± 8.3 | 390.3 ± 14.6 | 393.5 ± 14.2 | 386.5 ± 10.9 | 385.3 ± 16.8 | 369.0 ± 14.1 | 386.5 ± 13.2 |
| Change from baseline (BL)at 1h | 4.0 ± 2.8 | -2.0 ± 8.7 | -0.3 ± 3.8 | -3.5 ± 6.0 | 0.8 ± 4.0 | 0.8 ± 5.7 | 0.3 ± 7.6 | 28.8 ± 19.0 | 4.5 ± 19.1 | 5.8 ± 2.6 |
| Change from BL at 2h | 0.5 ± 7.9 | -4.0 ± 6.6 | -1.8 ± 7.9 | -4.8 ± 6.1 | -4.8 ± 3.0 | 1.5 ± 6.0 | 7.8 ± 10.0 | 28.5 ± 14.1 | 2.5 ± 13.4 | 1.8 ± 5.3 |
| Change from BL at 4h | 6.5 ± 9.4 | -2.2 ± 11.4 | -3.8 ± 3.3 | -4.3 ± 6.2 | 1.0 ± 5.7 | 3.8 ± 12.3 | 3.3 ± 7.2 | 26.0 ± 8.7 | 8.5 ± 17.7 | 0.3 ± 3.9 |
| Change from BL at 6h | 6.2 ± 3.6 | -2.7 ± 6.0 | 4.3 ± 6.3 | -4.0 ± 7.3 | -1.0 ± 8.3 | 5.8 ± 8.1 | 5.5 ± 2.5 | 26.0 ± 7.9 | 8.5 ± 12.0 | 6.0 ± 5.0 |
| Change from BL at 8h | -0.8 ± 7.3 | -7.2 ± 4.0 | -5.5 ± 7.4 | -1.8 ± 9.2 | 4.3 ± 10.3 | -1.8 ± 9.0 | 0.8 ± 7.5 | 23.3 ± 12.3 | -2.5 ± 13.4 | 0.5 ± 5.4 |
| Change from BL at 12h | 1.8 ± 6.7 | -5.2 ± 4.8 | -1.8 ± 2.6 | -7.3 ± 6.8 | 0.0 ± 4.7 | 0.0 ± 8.0 | 8.0 ± 0.8 | 19.3 ± 11.1 | 5.5 ± 7.8 | 3.3 ± 6.2 |
| Change from BL at 24h | 5.3 ± 12.4 | -7.5 ± 9.3 | -4.0 ± 7.3 | -4.8 ± 5.6 | 0.3 ± 6.2 | -4.3 ± 6.5 | 0.3 ± 9.7 | 11.3 ± 4.7 | -1.0 ± 8.5 | -3.8 ± 4.0 |
| Change from BL at FU | -0.3 ± 12.4 | 2.8 ± 7.9 | -1.3 ± 10.8 | 2.8 ± 8.0 | 2.8 ± 13.1 | 5.0 ± 6.1 | -5.0 ± 3.2 | 3.3 ± 7.6 | 5.5 ± 10.6 | 6.5 ± 13.0 |
Change from baseline in biochemistry related to Oxidative Phosphorylation (OXPHOS) (glutathione, lactate); MAD group
| ratio GSH/GSSG | MAD Group III | MAD Group IV | MAD Group V | Placebo |
|---|---|---|---|---|
| Ox glutathione (GSH)/Red Glutathati(GSSG) Day 1-0h | 872 ± 532 | 2083 ± 674 | 2275 ± 792 | 1584 ± 491 |
| GSH/GSSG Day 7-0h | 919 ± 196 | 1923 ± 433 | 1918 ± 1007 | 1694 ± 572 |
| GSH/GSSG Day 7-3h | 779 ± 87 | 2045 ± 338 | 1935 ± 699 | 1712 ± 465 |
| GSH/GSSG Day 7-6h | 1040 ± 335 | 2113 ± 687 | 1993 ± 863 | 1718 ± 542 |
| GSH/GSSG Day 7-12h | 1361 ± 606 | 1893 ± 279 | 1875 ± 697 | 1680 ± 657 |
| TEAE | Group I Placebo | Group II Placebo | SAD Group I 10mg | SAD Group II 30mg | SAD Group I 100mg | SAD Group II 300mg | SAD Group I 800mg | SAD Group II 2000mg | Group I Placebo + Food | Group I 100mg + Food | MAD Group III 200mg | MAD Group IV 400mg | MAD Group V 800mg | Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TEAE | 5 | 2 | 2 | 5 | 7 | 1 | 0 | 28 | 1 | 1 | 9 | 6 | 14 | 17 |
| Serious TEAE | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not related TEAE | 4 | 0 | 0 | 2 | 6 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 3 | 3 |
| Unlikely related | 0 | 2 | 2 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 1 |
| Possibly related | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 3 | 0 | 0 | 7 | 4 | 9 | 13 |
| Related | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 25 | 0 | 0 | 0 | 0 | 0 | 0 |
Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| cells 10^6/µL | Group I Placebo | Group II Placebo | SAD Group I 10mg | SAD Group II 30mg | SAD Group I 100mg | SAD Group II 300mg | SAD Group I 800mg | SAD Group II 2000mg | Group I Placebo + Food | Group I 100mg + Food |
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 4.947 ± 0.488 | 4.933 ± 0.307 | 4.793 ± 0.455 | 5.030 ± 0.458 | 4.953 ± 0.247 | 5.137 ± 0.393 | 4.973 ± 0.141 | 4.623 ± 0.395 | 5.095 ± 0.120 | 4.985 ± 0.343 |
| Change from BL at 24h | 0.200 ± 0.495 | 0.095 ± 0.260 | 0.063 ± 0.085 | 0.188 ± 0.153 | 0.170 ± 0.250 | 0.065 ± 0.197 | 0.173 ± 0.200 | 0.325 ± 0.185 | 0.185 ± 0.064 | 0.115 ± 0.208 |
| Change from BL at FU | 0.003 ± 0.215 | -0.013 ± 0.149 | 0.185 ± 0.104 | -0.052 ± 0.183 | 0.083 ± 0.127 | -0.147 ± 0.041 | -0.053 ± 0.209 | 0.125 ± 0.182 | -0.150 ± 0.339 | 0.050 ± 0.211 |
| mm/hr | Group I Placebo | Group II Placebo | SAD Group I 10mg | SAD Group II 30mg | SAD Group I 100mg | SAD Group II 300mg | SAD Group I 800mg | SAD Group II 2000mg | Group I Placebo + Food | Group I 100mg + Food |
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | 2.3 ± 1.4 | 2.8 ± 2.1 | 1.3 ± 0.5 | 1.8 ± 1.0 | 2.0 ± 1.4 | 3.0 ± 4.0 | 7.3 ± 8.5 | 4.0 ± 3.2 | 5.0 ± 2.8 | 2.5 ± 3.0 |
| Change from BL at 24h | 0.5 ± 0.5 | 0.3 ± 1.0 | 0.0 ± 0.0 | 1.0 ± 0.8 | 0.0 ± 0.8 | 0.3 ± 1.0 | 0.3 ± 0.6 | 3.0 ± 3.6 | -0.5 ± 0.7 | 1.0 ± 2.0 |
| Change from BL at FU | 0.3 ± 1.2 | 0.3 ± 1.5 | 0.8 ± 1.0 | 0.5 ± 1.7 | 0.5 ± 1.7 | 0.0 ± 0.0 | -2.3 ± 6.8 | 0.5 ± 1.0 | 0.0 ± 0.0 | 0.0 ± 0.0 |
| mm/hr | MAD Group III | MAD Group IV | MAD Group V | Placebo |
|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 4.0 ± 2.4 | 3.0 ± 1.8 | 2.0 ± 1.4 | 2.7 ± 1.8 |
| Change from BL at Day 3 | 2.0 ± 3.5 | 0.8 ± 0.5 | 0.5 ± 0.6 | 0.8 ± 1.7 |
| Change from BL at Day 8 | 4.8 ± 5.7 | 0.8 ± 2.2 | 2.5 ± 1.7 | 0.3 ± 1.4 |
| Change from BL at FU | 5.0 ± 8.2 | 1.3 ± 1.3 | 1.0 ± 0.8 | 2.2 ± 3.5 |
Hematocrit is a measure of the ratio of red blood cells (RBCs) in the blood by volume. Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| %red cells to the volume of whole blood. | Group I Placebo | Group II Placebo | SAD Group I 10mg | SAD Group II 30mg | SAD Group I 100mg | SAD Group II 300mg | SAD Group I 800mg | SAD Group II 2000mg | Group I Placebo + Food | Group I 100mg + Food |
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 43.77 ± 3.35 | 43.13 ± 2.79 | 43.10 ± 3.46 | 44.38 ± 3.28 | 42.98 ± 1.41 | 44.35 ± 2.88 | 44.05 ± 3.17 | 41.35 ± 1.68 | 44.35 ± 2.33 | 42.53 ± 1.50 |
| Change from BL at 24h | 0.53 ± 1.28 | 0.60 ± 2.10 | 0.75 ± 0.91 | 1.95 ± 1.41 | 1.42 ± 2.12 | 1.03 ± 2.11 | 1.33 ± 1.80 | 2.33 ± 1.87 | 1.90 ± 0.28 | 0.68 ± 1.92 |
| Change from BL at FU | -0.43 ± 1.70 | -0.65 ± 1.37 | 0.85 ± 1.45 | -0.93 ± 1.91 | 0.10 ± 1.66 | -2.02 ± 0.54 | -1.15 ± 2.17 | 0.07 ± 1.41 | -0.65 ± 3.04 | 0.55 ± 2.20 |
Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| pg/cell | Group I Placebo | Group II Placebo | SAD Group I 10mg | SAD Group II 30mg | SAD Group I 100mg | SAD Group II 300mg | SAD Group I 800mg | SAD Group II 2000mg | Group I Placebo + Food | Group I 100mg + Food |
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 30.32 ± 1.83 | 29.70 ± 0.98 | 30.78 ± 1.71 | 30.38 ± 0.49 | 30.00 ± 1.75 | 29.63 ± 0.68 | 30.28 ± 1.26 | 29.80 ± 1.16 | 30.25 ± 1.77 | 29.65 ± 2.13 |
| Change from BL at 24h - Day 1 | 0.08 ± 0.34 | 0.23 ± 0.59 | 0.17 ± 0.26 | -0.08 ± 0.26 | -0.15 ± 0.13 | -0.60 ± 0.80 | -0.25 ± 0.37 | 0.33 ± 0.41 | 0.25 ± 0.64 | 0.20 ± 0.34 |
| Change from BL at FU | -0.22 ± 0.15 | 0.05 ± 0.46 | -0.28 ± 0.57 | -0.23 ± 0.51 | -0.42 ± 0.37 | -0.28 ± 0.21 | -0.58 ± 0.22 | 0.12 ± 0.39 | -0.15 ± 0.35 | -0.08 ± 0.15 |
Erythrocyte mean corpuscular hemoglobin concentration (MCHC) is a measure of the average concentration of hemoglobin per red blood cell. Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| g/dL RBC | Group I Placebo | Group II Placebo | SAD Group I 10mg | SAD Group II 30mg | SAD Group I 100mg | SAD Group II 300mg | SAD Group I 800mg | SAD Group II 2000mg | Group I Placebo + Food | Group I 100mg + Food |
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 34.15 ± 0.34 | 33.98 ± 1.01 | 34.18 ± 0.46 | 34.38 ± 0.84 | 34.53 ± 0.45 | 34.33 ± 1.07 | 34.20 ± 0.65 | 33.25 ± 0.71 | 34.70 ± 0.57 | 34.68 ± 0.99 |
| Change from BL at 24h - Day 1 | -0.07 ± 0.32 | 0.43 ± 0.42 | 0.00 ± 0.35 | -0.27 ± 0.39 | -0.17 ± 0.15 | -1.05 ± 0.87 | -0.20 ± 0.42 | 0.82 ± 0.29 | 0.10 ± 0.57 | 0.45 ± 0.68 |
| Change from BL at FU | 0.17 ± 0.62 | 0.47 ± 0.42 | 0.27 ± 0.54 | 0.18 ± 0.60 | -0.05 ± 0.64 | 0.30 ± 0.48 | -0.13 ± 0.61 | 1.00 ± 0.12 | -0.60 ± 0.28 | -0.20 ± 0.42 |
Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| fL | Group I Placebo | Group II Placebo | SAD Group I 10mg | SAD Group II 30mg | SAD Group I 100mg | SAD Group II 300mg | SAD Group I 800mg | SAD Group II 2000mg | Group I Placebo + Food | Group I 100mg + Food |
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 88.75 ± 5.36 | 87.52 ± 3.71 | 90.15 ± 5.73 | 88.35 ± 2.88 | 86.93 ± 4.75 | 86.42 ± 2.83 | 88.55 ± 4.57 | 89.73 ± 4.24 | 87.10 ± 6.65 | 85.48 ± 4.36 |
| Change from BL at 24h | 0.45 ± 0.85 | -0.38 ± 1.09 | 0.35 ± 0.37 | 0.48 ± 0.41 | 0.00 ± 0.08 | 0.85 ± 0.73 | -0.27 ± 0.21 | -1.33 ± 0.72 | 0.60 ± 0.28 | -0.55 ± 0.79 |
| Change from BL at FU | -1.10 ± 1.85 | -1.03 ± 0.46 | -1.68 ± 0.90 | -0.92 ± 1.28 | -1.25 ± 1.54 | -1.52 ± 0.69 | -1.45 ± 1.02 | -2.30 ± 1.00 | 1.10 ± 0.28 | 0.20 ± 0.81 |
The baseline ECG recording consists of a triplicate recording (3 recordings of a least 3 complexes within a 5 minute window) prior to dosing on Day 1. For the evaluation of the corrected QT intervals the average of the 3 recordings will be taken as baseline. Other ECG recordings will be singlet (one recording of at least 3 complexes) prior to dosing, or around the expected Cmax on Day 1 or 7 for the multiple-dose part. QTcF is calculated as the quotient between the QT interval in milliseconds and the cube root of the RR interval in seconds, according to Fridericia's formula.
| msec | MAD Group III | MAD Group IV | MAD Group V | Placebo |
|---|---|---|---|---|
| Baseline (Pre-dose Day 1) | 397.3 ± 18.4 | 384.3 ± 21.7 | 388.5 ± 4.7 | 393.0 ± 18.8 |
| Change from BL at 2h - Day 1 | 0.5 ± 7.5 | 5.5 ± 8.1 | 7.3 ± 7.0 | 1.7 ± 5.3 |
| Change from BL at 24h - Day 1 | -4.3 ± 6.6 | 0.5 ± 5.7 | 3.3 ± 13.6 | -4.8 ± 3.7 |
| Change from BL Day 7 at 1h - Day 7 | -1.3 ± 10.2 | -3.0 ± 3.3 | -6.5 ± 8.1 | -2.2 ± 2.7 |
| Change from BL Day 7 at 2h - Day 7 | -3.5 ± 2.5 | -0.3 ± 8.2 | -0.8 ± 3.2 | -0.3 ± 10.1 |
| Change from BL Day 7 at 4h | -7.5 ± 4.7 | -3.8 ± 3.5 | -5.8 ± 7.7 | 3.0 ± 11.2 |
| Change from BL Day 7 BL at 6h - Day 7 | -1.8 ± 7.3 | 2.0 ± 4.7 | -7.3 ± 1.9 | -0.5 ± 21.0 |
| Change from BL Day 7 at 8h - Day 7 | -11.3 ± 3.2 | -3.8 ± 6.9 | -11.0 ± 5.3 | 0.8 ± 3.9 |
| Change from BL Day 7 at 12h - Day 7 | -4.3 ± 4.6 | -5.0 ± 3.5 | -10.0 ± 4.7 | 1.7 ± 6.0 |
| Change from BL at pre-dose Day 2 | -4.3 ± 6.6 | 0.5 ± 5.7 | 3.3 ± 13.6 | -4.8 ± 3.7 |
| Change from BL at pre-dose Day 3 | 0.5 ± 8.6 | 2.8 ± 6.4 | 10.5 ± 17.2 | -7.5 ± 6.8 |
| Change from BL at pre-dose Day 4 | 2.5 ± 14.6 | 0.5 ± 13.6 | 7.3 ± 10.2 | -6.7 ± 8.4 |
| Change from BL at pre-dose Day 5 | 6.0 ± 13.3 | 2.5 ± 7.2 | 10.8 ± 6.7 | -5.3 ± 7.3 |
| Change from BL at pre-dose Day 6 | -1.3 ± 12.5 | -1.5 ± 6.2 | 7.8 ± 8.0 | -8.2 ± 11.8 |
| Change from BL at pre-dose Day 7 | -1.0 ± 11.9 | 3.0 ± 9.5 | 13.5 ± 8.7 | -8.8 ± 9.2 |
| Change from BL at FU | -2.3 ± 5.0 | 4.0 ± 6.3 | -0.5 ± 14.4 | 6.7 ± 14.1 |
Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| cells 10^3/µL | Group I Placebo | Group II Placebo | SAD Group I 10mg | SAD Group II 30mg | SAD Group I 100mg | SAD Group II 300mg | SAD Group I 800mg | SAD Group II 2000mg | Group I Placebo + Food | Group I 100mg + Food |
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 4.435 ± 0.526 | 4.773 ± 0.548 | 4.313 ± 0.418 | 4.863 ± 0.372 | 4.395 ± 0.694 | 4.475 ± 0.733 | 4.853 ± 0.372 | 5.118 ± 0.647 | 5.815 ± 2.072 | 5.535 ± 1.467 |
| Change from BL at 24h | 0.343 ± 0.525 | -0.057 ± 0.359 | -0.033 ± 0.317 | 0.160 ± 0.329 | 0.257 ± 0.529 | 0.160 ± 0.753 | 0.528 ± 0.324 | 0.655 ± 0.666 | 0.220 ± 0.721 | -0.280 ± 0.555 |
| Change from BL at FU | 0.258 ± 0.309 | -0.203 ± 0.662 | 0.288 ± 0.211 | -0.073 ± 0.367 | 0.395 ± 0.617 | -0.287 ± 0.618 | 0.215 ± 0.266 | -0.320 ± 0.592 | -0.560 ± 1.202 | -0.745 ± 1.535 |
Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| cells/µL | Group I Placebo | Group II Placebo | SAD Group I 10mg | SAD Group II 30mg | SAD Group I 100mg | SAD Group II 300mg | SAD Group I 800mg | SAD Group II 2000mg | Group I Placebo + Food | Group I 100mg + Food |
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 1570.0 ± 227.0 | 1748.3 ± 441.1 | 1655.0 ± 200.4 | 1862.5 ± 548.2 | 1485.0 ± 169.2 | 1570.0 ± 273.1 | 1550.0 ± 275.3 | 1497.5 ± 707.6 | 2260.0 ± 975.8 | 1640.0 ± 243.2 |
| Change from BL at 24h | -13.3 ± 223.4 | -16.7 ± 347.3 | -45.0 ± 192.8 | -172.5 ± 227.1 | -27.5 ± 58.0 | 92.5 ± 225.6 | 287.5 ± 353.7 | 37.5 ± 159.9 | -135.0 ± 261.6 | -70.0 ± 177.6 |
| Change from BL at FU | 86.7 ± 265.3 | -45.0 ± 253.3 | 180.0 ± 186.5 | -92.5 ± 315.7 | 127.5 ± 425.2 | -32.5 ± 174.6 | 135.0 ± 294.2 | -7.5 ± 244.0 | -190.0 ± 410.1 | -27.5 ± 125.8 |
Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| cells/µL | Group I Placebo | Group II Placebo | SAD Group I 10mg | SAD Group II 30mg | SAD Group I 100mg | SAD Group II 300mg | SAD Group I 800mg | SAD Group II 2000mg | Group I Placebo + Food | Group I 100mg + Food |
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 2276.7 ± 551.2 | 2296.7 ± 658.7 | 2117.5 ± 369.2 | 2365.0 ± 820.8 | 2380.0 ± 679.0 | 2197.5 ± 835.9 | 2565.0 ± 462.6 | 2360.0 ± 438.1 | 2280.0 ± 169.7 | 3192.5 ± 1523.9 |
| Change from BL at 24h | 356.7 ± 336.9 | 98.3 ± 171.2 | 7.5 ± 196.7 | 410.0 ± 593.0 | 272.5 ± 419.1 | 165.0 ± 335.5 | 285.0 ± 155.0 | 440.0 ± 601.5 | 445.0 ± 459.6 | -122.5 ± 584.3 |
| Change from BL at FU | 205.0 ± 161.8 | -16.7 ± 335.4 | 90.0 ± 183.5 | 107.5 ± 252.1 | 255.0 ± 519.0 | -167.5 ± 480.7 | -12.5 ± 203.5 | -382.5 ± 232.9 | -205.0 ± 445.5 | -557.5 ± 1326.2 |
Hematocrit is a measure of the ratio of red blood cells (RBCs) in the blood by volume. Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value
| % of red cells to volume of whole blood. | MAD Group III | MAD Group IV | MAD Group V | Placebo |
|---|---|---|---|---|
| Baseline | 39.93 ± 1.20 | 43.40 ± 3.51 | 45.10 ± 1.33 | 43.30 ± 1.95 |
| Change from BL at Day 3 | 2.67 ± 1.94 | 1.17 ± 1.69 | 0.13 ± 0.45 | 1.70 ± 1.91 |
| Change from BL at Day 8 | 3.30 ± 1.24 | 1.22 ± 3.26 | 0.10 ± 1.22 | 1.93 ± 2.69 |
| Change from BL at FU | 0.92 ± 1.06 | -0.10 ± 3.26 | -1.05 ± 0.64 | -0.75 ± 2.32 |
Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| cells/µL | Group I Placebo | Group II Placebo | SAD Group I 10mg | SAD Group II 30mg | SAD Group I 100mg | SAD Group II 300mg | SAD Group I 800mg | SAD Group II 2000mg | Group I Placebo + Food | Group I 100mg + Food |
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 115.0 ± 50.1 | 191.7 ± 109.4 | 110.0 ± 49.7 | 137.5 ± 83.4 | 112.5 ± 36.9 | 200.0 ± 78.7 | 245.0 ± 233.6 | 110.0 ± 71.6 | 650.0 ± 792.0 | 152.5 ± 81.0 |
| Change from BL at 24h | -5.0 ± 16.4 | -50.0 ± 40.5 | -17.5 ± 9.6 | -22.5 ± 42.7 | -15.0 ± 12.9 | -37.5 ± 47.9 | -25.0 ± 33.2 | -25.0 ± 26.5 | -25.0 ± 7.1 | -30.0 ± 47.6 |
| Change from BL at FU | -13.3 ± 16.3 | -58.3 ± 93.5 | -17.5 ± 25.0 | -12.5 ± 43.5 | -2.5 ± 18.9 | -42.5 ± 61.3 | 77.5 ± 201.6 | -20.0 ± 18.3 | -125.0 ± 205.1 | -42.5 ± 42.7 |
Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| cells 10^3/µL | Group I Placebo | Group II Placebo | SAD Group I 10mg | SAD Group II 30mg | SAD Group I 100mg | SAD Group II 300mg | SAD Group I 800mg | SAD Group II 2000mg | Group I Placebo + Food | Group I 100mg + Food |
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 209.5 ± 45.9 | 204.0 ± 15.7 | 193.0 ± 31.9 | 223.0 ± 21.6 | 215.8 ± 64.0 | 203.8 ± 7.0 | 202.3 ± 54.5 | 160.1 ± 100.8 | 204.5 ± 67.2 | 215.8 ± 55.6 |
| Change from BL at 24h | 0.0 ± 9.7 | 4.8 ± 6.1 | 8.5 ± 12.4 | 2.3 ± 12.8 | 3.8 ± 20.3 | -14.5 ± 29.7 | 22.3 ± 13.5 | 23.0 ± 22.8 | 4.0 ± 7.1 | 0.3 ± 9.0 |
| Change from BL at FU | 11.8 ± 14.0 | 22.5 ± 15.7 | 23.8 ± 7.4 | 8.5 ± 24.3 | 16.3 ± 14.5 | 7.3 ± 7.9 | 15.8 ± 14.3 | 21.5 ± 22.4 | 1.0 ± 15.6 | 16.3 ± 12.5 |
Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value ateach timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| cells/µL | Group I Placebo | Group II Placebo | SAD Group I 10mg | SAD Group II 30mg | SAD Group I 100mg | SAD Group II 300mg | SAD Group I 800mg | SAD Group II 2000mg | Group I Placebo + Food | Group I 100mg + Food |
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 23.3 ± 5.2 | 25.0 ± 10.5 | 15.0 ± 5.8 | 30.0 ± 18.3 | 15.0 ± 10.0 | 32.5 ± 15.0 | 20.0 ± 11.5 | 22.5 ± 5.0 | 65.0 ± 63.6 | 25.0 ± 17.3 |
| Change from BL at 24h | -5.0 ± 8.4 | 0.0 ± 8.9 | 2.5 ± 5.0 | -7.5 ± 9.6 | 0.0 ± 0.0 | -5.0 ± 10.0 | 2.5 ± 5.0 | 5.0 ± 5.8 | -20.0 ± 14.1 | -2.5 ± 9.6 |
| Change from BL at FU | 0.0 ± 12.6 | -1.7 ± 7.5 | 5.0 ± 5.8 | -5.0 ± 10.0 | 7.5 ± 9.6 | -5.0 ± 12.9 | 20.0 ± 21.6 | 0.0 ± 8.2 | -15.0 ± 21.2 | -2.5 ± 5.0 |
Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| cells/µL | Group I Placebo | Group II Placebo | SAD Group I 10mg | SAD Group II 30mg | SAD Group I 100mg | SAD Group II 300mg | SAD Group I 800mg | SAD Group II 2000mg | Group I Placebo + Food | Group I 100mg + Food |
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 445.0 ± 78.2 | 496.7 ± 71.7 | 407.5 ± 79.3 | 455.0 ± 81.9 | 397.5 ± 133.0 | 467.5 ± 98.8 | 462.5 ± 147.1 | 470.0 ± 87.6 | 550.0 ± 70.7 | 512.5 ± 133.5 |
| Change from BL at 24h | 1.7 ± 46.7 | -81.7 ± 54.9 | 20.0 ± 78.3 | -45.0 ± 19.3 | 20.0 ± 122.7 | -62.5 ± 185.5 | -25.0 ± 112.4 | 2.5 ± 56.8 | -45.0 ± 21.2 | -55.0 ± 70.5 |
| Change from BL at FU | -21.7 ± 91.5 | -78.3 ± 74.9 | 30.0 ± 136.4 | -70.0 ± 94.9 | 5.0 ± 128.2 | -42.5 ± 86.6 | 0.0 ± 94.9 | -47.5 ± 63.4 | -20.0 ± 127.3 | -110.0 ± 128.3 |
Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| fL | MAD Group III | MAD Group IV | MAD Group V | Placebo |
|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 87.00 ± 0.62 | 89.32 ± 2.73 | 86.43 ± 1.29 | 89.02 ± 2.93 |
| Change from BL at Day 3 | -0.05 ± 0.40 | 0.52 ± 1.15 | 0.55 ± 0.71 | 0.40 ± 1.08 |
| Change from BL at Day 8 | -0.10 ± 1.30 | -0.43 ± 0.28 | 0.32 ± 0.90 | 0.28 ± 0.95 |
| Change from BL at FU | 0.60 ± 0.74 | -0.55 ± 0.73 | 1.22 ± 1.31 | 0.65 ± 0.77 |
Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| g/dL | MAD Group III | MAD Group IV | MAD Group V | Placebo |
|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 13.68 ± 0.59 | 15.23 ± 1.38 | 15.68 ± 0.64 | 14.82 ± 0.67 |
| Change from BL at Day 3 | 1.05 ± 0.66 | 0.42 ± 0.74 | 0.17 ± 0.22 | 0.62 ± 0.50 |
| Change from BL at Day 8 | 1.35 ± 0.37 | 0.55 ± 1.22 | 0.27 ± 0.60 | 0.75 ± 0.83 |
| Change from BL at FU | 0.30 ± 0.49 | -0.05 ± 1.11 | -0.38 ± 0.47 | -0.35 ± 0.63 |
Blood samples were collected from participants at the indicated time points for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each time point are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| cells 10^3/µL | MAD Group III | MAD Group IV | MAD Group V | Placebo |
|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 5.463 ± 0.579 | 4.753 ± 0.410 | 5.378 ± 1.221 | 4.583 ± 0.487 |
| Change from BL at Day 3 | -0.435 ± 0.631 | 0.480 ± 0.787 | 0.895 ± 0.940 | 0.277 ± 0.932 |
| Change from BL at Day 8 | 0.223 ± 2.237 | 0.480 ± 0.252 | 0.795 ± 0.178 | 0.563 ± 0.983 |
| Change from BL at FU | 0.060 ± 2.519 | 0.230 ± 0.870 | 1.340 ± 0.546 | -0.140 ± 0.930 |
Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| cells/µL | MAD Group III | MAD Group IV | MAD Group V | Placebo |
|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 3077.5 ± 569.5 | 2602.5 ± 582.4 | 2935.0 ± 966.6 | 2483.3 ± 583.6 |
| Change from BL at Day 3 | -567.5 ± 667.9 | 350.0 ± 602.4 | 437.5 ± 505.3 | 81.7 ± 540.7 |
| Change from BL at Day 8 | 105.0 ± 2079.7 | 312.5 ± 355.1 | 537.5 ± 174.6 | 261.0 ± 634.9 |
| Change from BL at FU | 185.0 ± 2317.4 | 177.5 ± 827.7 | 1010.0 ± 622.7 | -75.0 ± 532.1 |
Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| g/dL RBC | MAD Group III | MAD Group IV | MAD Group V | Placebo |
|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 34.28 ± 1.08 | 35.05 ± 0.37 | 34.75 ± 0.62 | 34.23 ± 0.37 |
| Change from BL at Day 3 | 0.30 ± 0.22 | 0.05 ± 0.62 | 0.30 ± 0.39 | 0.08 ± 0.48 |
| Change from BL at Day 8 | 0.47 ± 0.43 | 0.25 ± 0.26 | 0.50 ± 0.44 | 0.17 ± 0.38 |
| Change from BL at FU | -0.08 ± 0.33 | 0.00 ± 0.27 | 0.00 ± 0.65 | -0.22 ± 0.44 |
Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| cells/µL | MAD Group III | MAD Group IV | MAD Group V | Placebo |
|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 1627.5 ± 656.0 | 1498.5 ± 125.1 | 1750.0 ± 187.4 | 1508.3 ± 317.1 |
| Change from BL at Day 3 | 87.5 ± 177.8 | 159.0 ± 188.6 | 390.0 ± 297.4 | 215.0 ± 372.3 |
| Change from BL at Day 8 | 12.5 ± 378.5 | 124.0 ± 148.8 | 237.5 ± 208.1 | 283.3 ± 402.6 |
| Change from BL at FU | -55.0 ± 257.5 | 39.0 ± 382.3 | 262.5 ± 220.2 | 5.0 ± 465.9 |
Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| pg/cell | MAD Group III | MAD Group IV | MAD Group V | Placebo |
|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 29.80 ± 0.91 | 31.33 ± 1.24 | 30.03 ± 0.49 | 30.47 ± 0.97 |
| Change from BL at Day 3 | 0.25 ± 0.13 | 0.23 ± 0.39 | 0.45 ± 0.26 | 0.20 ± 0.25 |
| Change from BL at Day 8 | 0.40 ± 0.40 | 0.12 ± 0.22 | 0.57 ± 0.62 | 0.25 ± 0.33 |
| Change from BL at FU | 0.15 ± 0.47 | -0.20 ± 0.08 | 0.40 ± 0.41 | 0.02 ± 0.25 |
Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| cells 10^6/µL | MAD Group III | MAD Group IV | MAD Group V | Placebo |
|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 4.588 ± 0.108 | 4.858 ± 0.380 | 5.217 ± 0.138 | 4.873 ± 0.360 |
| Change from BL at Day 3 | 0.313 ± 0.234 | 0.100 ± 0.193 | -0.017 ± 0.060 | 0.167 ± 0.196 |
| Change from BL at Day 8 | 0.385 ± 0.139 | 0.160 ± 0.362 | -0.007 ± 0.144 | 0.198 ± 0.249 |
| Change from BL at FU | 0.075 ± 0.099 | 0.020 ± 0.350 | -0.192 ± 0.145 | -0.120 ± 0.237 |
Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| cells/µL | MAD Group III | MAD Group IV | MAD Group V | Placebo |
|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 212.5 ± 79.3 | 183.5 ± 84.6 | 127.5 ± 45.7 | 141.7 ± 96.2 |
| Change from BL at Day 3 | -40.0 ± 52.3 | -31.0 ± 53.2 | 7.5 ± 20.6 | -28.3 ± 43.6 |
| Change from BL at Day 8 | -47.5 ± 87.3 | -28.5 ± 66.0 | -10.0 ± 27.1 | -22.7 ± 56.4 |
| Change from BL at FU | -27.5 ± 131.8 | 31.5 ± 26.5 | -17.5 ± 27.5 | -45.0 ± 76.4 |
Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| cells/µL | MAD Group III | MAD Group IV | MAD Group V | Placebo |
|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 505.0 ± 44.3 | 424.0 ± 140.9 | 530.0 ± 134.9 | 418.3 ± 61.5 |
| Change from BL at Day 3 | 75.0 ± 151.5 | -11.5 ± 142.6 | 57.5 ± 115.0 | 1.7 ± 64.3 |
| Change from BL at Day 8 | 137.5 ± 374.6 | 76.0 ± 95.3 | 27.5 ± 42.7 | 24.3 ± 53.1 |
| Change from BL at FU | -52.5 ± 176.7 | -21.5 ± 140.5 | 82.5 ± 76.8 | -43.3 ± 85.0 |
Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| cells 10^3/µL | MAD Group III | MAD Group IV | MAD Group V | Placebo |
|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 207.3 ± 24.6 | 211.5 ± 41.2 | 199.8 ± 25.6 | 206.7 ± 48.1 |
| Change from BL at Day 3 | 15.5 ± 14.5 | 17.5 ± 9.5 | 27.5 ± 8.4 | 17.3 ± 15.1 |
| Change from BL at Day 8 | 44.8 ± 37.6 | 4.8 ± 22.3 | 31.3 ± 13.9 | 29.5 ± 12.5 |
| Change from BL at FU | 63.8 ± 41.3 | 5.5 ± 21.9 | 33.8 ± 20.0 | 21.7 ± 10.7 |
Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| cells/µL | MAD Group III | MAD Group IV | MAD Group V | Placebo |
|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 30.0 ± 8.2 | 34.0 ± 10.8 | 20.0 ± 11.5 | 23.3 ± 10.3 |
| Change from BL at Day 3 | 7.5 ± 17.1 | 8.5 ± 17.4 | 2.5 ± 5.0 | 3.3 ± 8.2 |
| Change from BL at Day 8 | 12.5 ± 20.6 | -6.5 ± 17.0 | 5.0 ± 12.9 | 4.0 ± 14.7 |
| Change from BL at FU | 7.5 ± 15.0 | 1.0 ± 6.6 | 2.5 ± 12.6 | 5.0 ± 18.7 |
Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| U/L | Group I Placebo | Group II Placebo | SAD Group I 10mg | SAD Group II 30mg | SAD Group I 100mg | SAD Group II 300mg | SAD Group I 800mg | SAD Group II 2000mg | Group I Placebo + Food | Group I 100mg + Food |
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 20.5 ± 5.9 | 16.8 ± 2.7 | 19.3 ± 4.3 | 17.5 ± 3.8 | 18.3 ± 9.2 | 20.8 ± 4.4 | 18.8 ± 6.1 | 17.0 ± 2.9 | 19.5 ± 2.1 | 18.5 ± 4.8 |
| Change from BL at 24h | -2.7 ± 1.2 | 0.3 ± 2.1 | -0.5 ± 1.3 | 1.8 ± 3.0 | -2.5 ± 4.7 | -0.3 ± 1.0 | -1.0 ± 3.3 | 0.5 ± 2.5 | -1.0 ± 2.8 | -1.0 ± 2.2 |
| Change from BL at FU | 0.3 ± 1.0 | 3.3 ± 5.8 | 2.8 ± 6.2 | 4.8 ± 7.6 | 0.3 ± 4.9 | 0.5 ± 7.6 | 1.3 ± 3.6 | 1.0 ± 3.7 | 3.5 ± 6.4 | 0.0 ± 1.4 |
Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| g/L | Group I Placebo | Group II Placebo | SAD Group I 10mg | SAD Group II 30mg | SAD Group I 100mg | SAD Group II 300mg | SAD Group I 800mg | SAD Group II 2000mg | Group I Placebo + Food | Group I 100mg + Food |
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 67.5 ± 4.9 | 65.5 ± 5.2 | 67.0 ± 4.1 | 67.3 ± 2.2 | 65.3 ± 5.0 | 66.0 ± 1.8 | 66.3 ± 3.5 | 66.0 ± 1.4 | 66.5 ± 2.1 | 66.3 ± 5.4 |
| Change from BL at 24h | 1.3 ± 2.7 | 3.7 ± 3.6 | 1.5 ± 1.0 | 3.0 ± 2.4 | 2.8 ± 4.0 | 6.0 ± 1.6 | 3.0 ± 5.0 | 9.3 ± 4.8 | 2.5 ± 4.9 | 2.3 ± 4.6 |
| Change from BL at FU | 1.5 ± 2.9 | 3.3 ± 3.1 | 4.0 ± 2.2 | 1.8 ± 3.9 | 3.3 ± 1.7 | 0.8 ± 1.7 | 0.0 ± 2.2 | 4.8 ± 3.3 | 1.0 ± 1.4 | 2.3 ± 3.2 |
Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value
| U/L | Group I Placebo | Group II Placebo | SAD Group I 10mg | SAD Group II 30mg | SAD Group I 100mg | SAD Group II 300mg | SAD Group I 800mg | SAD Group II 2000mg | Group I Placebo + Food | Group I 100mg + Food |
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 23.5 ± 26.7 | 19.0 ± 14.1 | 24.0 ± 20.0 | 23.0 ± 16.2 | 12.0 ± 6.8 | 17.3 ± 12.1 | 30.0 ± 30.8 | 21.3 ± 17.2 | 29.0 ± 14.1 | 13.5 ± 5.1 |
| Change from BL at 24h | -0.8 ± 1.7 | 1.2 ± 2.1 | 0.0 ± 0.8 | 0.8 ± 1.7 | 0.3 ± 1.3 | 1.3 ± 0.5 | -0.5 ± 4.4 | 3.8 ± 3.1 | 0.0 ± 2.8 | 0.8 ± 1.0 |
| Change from BL at FU | -4.0 ± 13.8 | 10.0 ± 16.1 | -1.3 ± 4.5 | 13.8 ± 18.4 | 2.5 ± 2.4 | 11.3 ± 20.5 | -7.3 ± 15.6 | 1.8 ± 2.5 | 3.5 ± 3.5 | 1.0 ± 0.8 |
Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| U/L | Group I Placebo | Group II Placebo | SAD Group I 10mg | SAD Group II 30mg | SAD Group I 100mg | SAD Group II 300mg | SAD Group I 800mg | SAD Group II 2000mg | Group I Placebo + Food | Group I 100mg + Food |
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 62.0 ± 18.6 | 64.0 ± 19.8 | 66.0 ± 18.5 | 75.0 ± 32.2 | 66.0 ± 25.0 | 68.3 ± 28.0 | 53.3 ± 10.2 | 49.0 ± 8.9 | 54.5 ± 2.1 | 62.3 ± 21.7 |
| Change from BL at 24h | -0.2 ± 3.0 | 1.7 ± 3.5 | 1.0 ± 2.8 | -1.8 ± 8.1 | 1.0 ± 4.7 | 3.8 ± 4.6 | 1.3 ± 3.6 | 6.8 ± 3.5 | 2.0 ± 2.8 | 0.8 ± 3.6 |
| Change from BL at FU | -1.5 ± 9.0 | 1.7 ± 6.3 | 1.8 ± 3.5 | -3.8 ± 18.2 | 1.5 ± 3.4 | -1.5 ± 11.3 | -2.0 ± 5.4 | 4.3 ± 1.5 | 2.0 ± 2.8 | -0.8 ± 4.9 |
Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| mg/dL | Group I Placebo | Group II Placebo | SAD Group I 10mg | SAD Group II 30mg | SAD Group I 100mg | SAD Group II 300mg | SAD Group I 800mg | SAD Group II 2000mg | Group I Placebo + Food | Group I 100mg + Food |
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 0.927 ± 0.058 | 0.768 ± 0.108 | 0.903 ± 0.028 | 0.810 ± 0.091 | 0.838 ± 0.035 | 0.735 ± 0.108 | 0.918 ± 0.043 | 0.838 ± 0.213 | 0.935 ± 0.078 | 0.863 ± 0.024 |
| Change from BL at 24h | 0.023 ± 0.050 | 0.067 ± 0.033 | 0.080 ± 0.054 | 0.053 ± 0.076 | 0.040 ± 0.041 | 0.115 ± 0.025 | 0.090 ± 0.043 | 0.075 ± 0.112 | 0.015 ± 0.106 | 0.038 ± 0.071 |
| Change from BL at FU | -0.003 ± 0.048 | 0.065 ± 0.048 | 0.012 ± 0.039 | 0.073 ± 0.056 | 0.088 ± 0.068 | 0.063 ± 0.028 | -0.020 ± 0.096 | -0.017 ± 0.085 | -0.080 ± 0.071 | 0.063 ± 0.068 |
Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| mmol/L | Group I Placebo | Group II Placebo | SAD Group I 10mg | SAD Group II 30mg | SAD Group I 100mg | SAD Group II 300mg | SAD Group I 800mg | SAD Group II 2000mg | Group I Placebo + Food | Group I 100mg + Food |
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 102.7 ± 2.7 | 104.0 ± 1.7 | 103.8 ± 1.7 | 104.0 ± 0.8 | 102.3 ± 2.4 | 103.0 ± 1.4 | 103.3 ± 1.5 | 103.8 ± 1.7 | 100.5 ± 2.1 | 101.5 ± 2.1 |
| Change from BL at 24h | -0.5 ± 1.4 | -2.5 ± 1.4 | -1.5 ± 2.5 | -3.5 ± 0.6 | 0.0 ± 1.8 | -2.8 ± 1.0 | -1.3 ± 1.0 | -3.5 ± 1.7 | 2.0 ± 0.0 | -0.5 ± 1.3 |
| Change from BL at FU | -1.5 ± 3.5 | -3.2 ± 2.2 | -2.5 ± 2.1 | -3.5 ± 1.3 | -0.8 ± 2.2 | -2.3 ± 2.2 | -0.8 ± 3.5 | -3.0 ± 0.0 | 3.5 ± 3.5 | 0.0 ± 2.7 |
Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| mg/dL | Group I Placebo | Group II Placebo | SAD Group I 10mg | SAD Group II 30mg | SAD Group I 100mg | SAD Group II 300mg | SAD Group I 800mg | SAD Group II 2000mg | Group I Placebo + Food | Group I 100mg + Food |
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 0.82 ± 0.32 | 0.75 ± 0.60 | 1.03 ± 0.83 | 0.68 ± 0.33 | 1.18 ± 1.03 | 0.53 ± 0.13 | 0.63 ± 0.22 | 0.31 ± 0.19 | 0.45 ± 0.21 | 1.10 ± 1.33 |
| Change from BL at 24h | 0.30 ± 0.26 | 0.12 ± 0.08 | 0.40 ± 0.08 | 0.38 ± 0.13 | -0.00 ± 0.18 | 0.28 ± 0.10 | -0.03 ± 0.15 | 0.31 ± 0.09 | 0.15 ± 0.07 | 0.27 ± 0.17 |
| Change from BL at FU | 0.13 ± 0.42 | -0.02 ± 0.40 | 0.05 ± 0.13 | 0.13 ± 0.13 | -0.18 ± 0.33 | 0.20 ± 0.18 | 0.00 ± 0.29 | 0.21 ± 0.10 | 0.10 ± 0.14 | -0.10 ± 0.56 |
Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| U/L | Group I Placebo | Group II Placebo | SAD Group I 10mg | SAD Group II 30mg | SAD Group I 100mg | SAD Group II 300mg | SAD Group I 800mg | SAD Group II 2000mg | Group I Placebo + Food | Group I 100mg + Food |
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 20.2 ± 11.3 | 17.2 ± 6.9 | 19.3 ± 3.2 | 20.0 ± 10.1 | 15.0 ± 6.9 | 19.3 ± 6.6 | 22.8 ± 12.8 | 17.8 ± 6.8 | 19.0 ± 1.4 | 15.0 ± 5.7 |
| Change from BL at 24h | -1.2 ± 2.2 | -0.3 ± 3.2 | 0.8 ± 2.9 | -1.3 ± 3.5 | 1.3 ± 1.3 | -0.3 ± 2.8 | -2.0 ± 3.6 | 0.3 ± 3.9 | 1.5 ± 2.1 | 1.5 ± 1.0 |
| Change from BL at FU | -1.0 ± 4.5 | 5.7 ± 17.7 | 2.3 ± 7.8 | 8.3 ± 18.0 | 1.8 ± 2.6 | 6.0 ± 21.5 | -2.3 ± 5.7 | -1.0 ± 2.9 | 7.5 ± 9.2 | 1.8 ± 2.1 |
Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| U/L | Group I Placebo | Group II Placebo | SAD Group I 10mg | SAD Group II 30mg | SAD Group I 100mg | SAD Group II 300mg | SAD Group I 800mg | SAD Group II 2000mg | Group I Placebo + Food | Group I 100mg + Food |
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 118.2 ± 39.3 | 78.7 ± 5.9 | 181.8 ± 59.3 | 78.8 ± 13.4 | 209.3 ± 223.6 | 82.3 ± 28.0 | 68.5 ± 49.5 | 89.5 ± 45.4 | 82.5 ± 89.8 | 81.3 ± 29.4 |
| Change from BL at 24h | -34.3 ± 23.1 | -14.0 ± 3.3 | -51.0 ± 34.6 | -12.8 ± 1.9 | -97.8 ± 137.1 | -15.5 ± 14.1 | -14.0 ± 23.6 | -14.8 ± 26.9 | -31.5 ± 43.1 | -14.8 ± 8.3 |
| Change from BL at FU | 13.0 ± 43.7 | 16.7 ± 35.7 | -17.3 ± 88.6 | 24.5 ± 39.4 | -110.0 ± 173.1 | 6.0 ± 7.5 | 15.8 ± 16.9 | 7.0 ± 61.9 | 21.5 ± 17.7 | 18.0 ± 31.2 |
Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| mg/dL | Group I Placebo | Group II Placebo | SAD Group I 10mg | SAD Group II 30mg | SAD Group I 100mg | SAD Group II 300mg | SAD Group I 800mg | SAD Group II 2000mg | Group I Placebo + Food | Group I 100mg + Food |
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 27.5 ± 9.3 | 24.7 ± 4.5 | 30.0 ± 8.4 | 26.0 ± 7.3 | 24.0 ± 2.4 | 25.3 ± 4.1 | 29.3 ± 10.6 | 34.8 ± 7.7 | 38.5 ± 6.4 | 25.8 ± 5.7 |
| Change from BL at 24h | 0.0 ± 3.9 | 0.2 ± 4.4 | -2.5 ± 5.0 | -0.3 ± 2.5 | 0.0 ± 2.8 | -0.5 ± 5.2 | -1.0 ± 4.7 | -4.0 ± 8.6 | -9.0 ± 1.4 | -0.5 ± 3.3 |
| Change from BL at FU | 1.2 ± 7.1 | 0.5 ± 7.7 | -0.8 ± 3.9 | 2.3 ± 7.7 | 0.3 ± 4.5 | -2.3 ± 7.3 | -0.3 ± 5.4 | -6.8 ± 11.8 | -8.0 ± 4.2 | -1.5 ± 4.7 |
Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| mmol/L | Group I Placebo | Group II Placebo | SAD Group I 10mg | SAD Group II 30mg | SAD Group I 100mg | SAD Group II 300mg | SAD Group I 800mg | SAD Group II 2000mg | Group I Placebo + Food | Group I 100mg + Food |
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 141.8 ± 1.0 | 142.5 ± 1.2 | 141.5 ± 0.6 | 142.8 ± 1.0 | 141.5 ± 1.7 | 142.0 ± 0.8 | 142.3 ± 1.3 | 143.3 ± 1.0 | 139.5 ± 0.7 | 140.5 ± 1.0 |
| Change from BL at 24h | -0.2 ± 1.6 | -0.7 ± 0.8 | -0.3 ± 2.2 | -2.0 ± 1.4 | -0.8 ± 2.2 | -1.0 ± 0.8 | 0.5 ± 0.6 | -1.3 ± 1.0 | 2.5 ± 2.1 | 1.0 ± 2.6 |
| Change from BL at FU | -0.3 ± 2.4 | -1.8 ± 2.0 | 0.0 ± 2.7 | -2.3 ± 2.2 | 0.8 ± 1.3 | -2.0 ± 0.8 | 0.5 ± 2.4 | -2.8 ± 1.3 | 4.5 ± 0.7 | 1.8 ± 0.5 |
Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| mmol/L | Group I Placebo | Group II Placebo | SAD Group I 10mg | SAD Group II 30mg | SAD Group I 100mg | SAD Group II 300mg | SAD Group I 800mg | SAD Group II 2000mg | Group I Placebo + Food | Group I 100mg + Food |
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 4.25 ± 0.18 | 4.27 ± 0.18 | 4.25 ± 0.13 | 4.18 ± 0.25 | 4.03 ± 0.19 | 4.33 ± 0.13 | 4.28 ± 0.32 | 4.50 ± 0.18 | 4.00 ± 0.00 | 4.20 ± 0.22 |
| Change from BL at 24h | 0.17 ± 0.18 | 0.17 ± 0.21 | 0.07 ± 0.31 | 0.23 ± 0.33 | 0.30 ± 0.22 | -0.05 ± 0.26 | 0.12 ± 0.10 | -0.10 ± 0.16 | 0.25 ± 0.07 | 0.15 ± 0.34 |
| Change from BL at FU | 0.25 ± 0.10 | 0.10 ± 0.26 | 0.30 ± 0.22 | 0.20 ± 0.29 | 0.50 ± 0.22 | 0.10 ± 0.27 | 0.08 ± 0.36 | -0.05 ± 0.10 | 0.30 ± 0.14 | 0.33 ± 0.17 |
Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| mmol/L | Group I Placebo | Group II Placebo | SAD Group I 10mg | SAD Group II 30mg | SAD Group I 100mg | SAD Group II 300mg | SAD Group I 800mg | SAD Group II 2000mg | Group I Placebo + Food | Group I 100mg + Food |
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 1.042 ± 0.066 | 0.998 ± 0.122 | 1.120 ± 0.117 | 1.085 ± 0.133 | 1.023 ± 0.081 | 0.983 ± 0.165 | 1.088 ± 0.142 | 1.128 ± 0.193 | 1.410 ± 0.552 | 1.105 ± 0.154 |
| Change from BL at 24h | 0.033 ± 0.126 | -0.045 ± 0.094 | -0.035 ± 0.169 | -0.133 ± 0.105 | 0.045 ± 0.172 | -0.060 ± 0.111 | 0.032 ± 0.116 | -0.090 ± 0.164 | -0.180 ± 0.999 | -0.015 ± 0.079 |
| Change from BL at FU | -0.020 ± 0.116 | 0.030 ± 0.172 | -0.077 ± 0.126 | -0.018 ± 0.182 | 0.003 ± 0.046 | -0.070 ± 0.153 | -0.090 ± 0.121 | -0.105 ± 0.135 | -0.395 ± 0.205 | -0.080 ± 0.097 |
Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| mmol/L | Group I Placebo | Group II Placebo | SAD Group I 10mg | SAD Group II 30mg | SAD Group I 100mg | SAD Group II 300mg | SAD Group I 800mg | SAD Group II 2000mg | Group I Placebo + Food | Group I 100mg + Food |
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 2.380 ± 0.073 | 2.303 ± 0.087 | 2.290 ± 0.114 | 2.288 ± 0.030 | 2.373 ± 0.116 | 2.358 ± 0.069 | 2.353 ± 0.102 | 2.323 ± 0.044 | 2.340 ± 0.000 | 2.360 ± 0.118 |
| Change from BL at 24h | 0.033 ± 0.045 | 0.095 ± 0.066 | 0.098 ± 0.050 | 0.093 ± 0.028 | 0.058 ± 0.105 | 0.085 ± 0.059 | 0.078 ± 0.075 | 0.148 ± 0.055 | -0.005 ± 0.021 | 0.075 ± 0.088 |
| Change from BL at FU | 0.010 ± 0.041 | 0.062 ± 0.075 | 0.085 ± 0.070 | 0.073 ± 0.098 | 0.042 ± 0.030 | -0.032 ± 0.006 | -0.005 ± 0.033 | 0.090 ± 0.059 | -0.065 ± 0.049 | 0.055 ± 0.039 |
Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| mg/dL | Group I Placebo | Group II Placebo | SAD Group I 10mg | SAD Group II 30mg | SAD Group I 100mg | SAD Group II 300mg | SAD Group I 800mg | SAD Group II 2000mg | Group I Placebo + Food | Group I 100mg + Food |
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 5.52 ± 0.84 | 4.85 ± 0.84 | 5.75 ± 0.42 | 4.80 ± 0.37 | 5.48 ± 0.82 | 4.75 ± 0.79 | 5.48 ± 1.07 | 5.10 ± 0.96 | 5.45 ± 0.21 | 5.50 ± 1.41 |
| Change from BL at 24h | -0.25 ± 0.40 | -0.13 ± 0.23 | -0.28 ± 0.25 | -0.20 ± 0.24 | -0.30 ± 0.12 | -0.25 ± 0.24 | -0.20 ± 0.32 | 0.15 ± 0.42 | -0.60 ± 0.28 | -0.28 ± 0.40 |
| Change from BL at FU | 0.28 ± 0.26 | 0.32 ± 0.50 | 0.22 ± 0.79 | 0.40 ± 0.43 | 0.35 ± 0.53 | 0.30 ± 0.08 | 0.18 ± 0.68 | 0.23 ± 0.22 | 0.40 ± 0.28 | 0.33 ± 0.51 |
Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| pg/mL | Group I Placebo | Group II Placebo | SAD Group I 10mg | SAD Group II 30mg | SAD Group I 100mg | SAD Group II 300mg | SAD Group I 800mg | SAD Group II 2000mg | Group I Placebo + Food | Group I 100mg + Food |
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 3.65 ± 0.35 | 3.23 ± 0.12 | 3.73 ± 0.21 | 3.40 ± 0.22 | 3.48 ± 0.30 | 3.18 ± 0.17 | 3.18 ± 0.17 | 3.33 ± 0.19 | 3.60 ± 0.14 | 3.63 ± 0.41 |
| Change from BL at 24h | -0.35 ± 0.28 | -0.10 ± 0.24 | -0.22 ± 0.17 | 0.05 ± 0.31 | -0.07 ± 0.10 | -0.23 ± 0.10 | -0.23 ± 0.36 | -0.13 ± 0.15 | -0.40 ± 0.00 | -0.25 ± 0.17 |
| Change from BL at FU | -0.30 ± 0.28 | 0.42 ± 0.23 | -0.23 ± 0.13 | 0.30 ± 0.23 | -0.13 ± 0.17 | 0.50 ± 0.34 | 0.05 ± 0.13 | 0.20 ± 0.08 | -0.30 ± 0.14 | -0.28 ± 0.15 |
Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| U/L | Group I Placebo | Group II Placebo | SAD Group I 10mg | SAD Group II 30mg | SAD Group I 100mg | SAD Group II 300mg | SAD Group I 800mg | SAD Group II 2000mg | Group I Placebo + Food | Group I 100mg + Food |
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 31.0 ± 8.2 | 34.8 ± 16.2 | 39.0 ± 9.8 | 29.3 ± 12.7 | 27.3 ± 7.5 | 33.0 ± 9.2 | 30.0 ± 8.0 | 25.5 ± 6.2 | 42.0 ± 14.1 | 31.1 ± 11.8 |
| Change from BL at 24h | -1.5 ± 3.1 | -7.5 ± 18.5 | -6.3 ± 6.8 | -1.8 ± 2.9 | 1.3 ± 0.5 | 7.3 ± 16.5 | -1.3 ± 3.4 | -4.8 ± 5.1 | -0.5 ± 2.1 | -2.5 ± 5.1 |
| Change from BL at FU | -1.0 ± 2.3 | -1.0 ± 5.5 | -4.5 ± 12.4 | 8.0 ± 27.2 | 1.5 ± 3.0 | -5.0 ± 3.7 | -2.0 ± 6.5 | 9.3 ± 19.8 | -7.0 ± 4.2 | -2.5 ± 3.0 |
Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| mg/dL | Group I Placebo | Group II Placebo | SAD Group I 10mg | SAD Group II 30mg | SAD Group I 100mg | SAD Group II 300mg | SAD Group I 800mg | SAD Group II 2000mg | Group I Placebo + Food | Group I 100mg + Food |
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 85.0 ± 7.3 | 86.8 ± 8.9 | 84.8 ± 7.4 | 88.5 ± 12.2 | 77.8 ± 5.7 | 86.3 ± 9.4 | 87.0 ± 4.2 | 95.5 ± 18.7 | 84.0 ± 5.7 | 78.8 ± 3.8 |
| Change from BL at 24h | -1.0 ± 3.2 | 1.2 ± 5.2 | 2.0 ± 3.7 | -2.0 ± 3.2 | 7.0 ± 4.5 | -1.0 ± 1.4 | 0.5 ± 3.1 | -2.3 ± 1.0 | 4.0 ± 1.4 | 3.3 ± 1.9 |
| Change from BL at FU | -0.2 ± 7.0 | 5.5 ± 6.9 | -0.3 ± 7.7 | 6.3 ± 6.7 | 7.3 ± 6.2 | 0.5 ± 5.9 | -1.3 ± 5.4 | -1.5 ± 1.7 | 2.0 ± 8.5 | 6.3 ± 3.8 |
Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| g/L | Group I Placebo | Group II Placebo | SAD Group I 10mg | SAD Group II 30mg | SAD Group I 100mg | SAD Group II 300mg | SAD Group I 800mg | SAD Group II 2000mg | Group I Placebo + Food | Group I 100mg + Food |
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 46.2 ± 3.1 | 45.0 ± 2.8 | 45.3 ± 3.9 | 45.0 ± 1.2 | 45.3 ± 3.4 | 46.0 ± 1.4 | 44.0 ± 1.2 | 44.3 ± 1.5 | 44.0 ± 1.4 | 45.8 ± 3.1 |
| Change from BL at 24h | -0.3 ± 1.2 | 1.7 ± 1.5 | 0.3 ± 1.5 | 2.0 ± 2.6 | 1.5 ± 3.7 | 3.5 ± 1.3 | 1.5 ± 3.1 | 5.3 ± 2.6 | 0.5 ± 2.1 | 0.0 ± 2.7 |
| Change from BL at FU | 0.2 ± 1.8 | 2.0 ± 1.4 | 2.3 ± 1.5 | 2.0 ± 2.8 | 1.0 ± 1.2 | 0.5 ± 1.3 | 0.0 ± 0.8 | 3.5 ± 2.1 | 0.0 ± 0.0 | 05 ± 1.7 |
Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| mg/dL | Group I Placebo | Group II Placebo | SAD Group I 10mg | SAD Group II 30mg | SAD Group I 100mg | SAD Group II 300mg | SAD Group I 800mg | SAD Group II 2000mg | Group I Placebo + Food | Group I 100mg + Food |
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 176.0 ± 47.7 | 151.0 ± 26.6 | 146.3 ± 37.5 | 149.0 ± 38.3 | 146.5 ± 49.7 | 167.5 ± 42.3 | 212.8 ± 48.2 | 174.5 ± 34.5 | 200.5 ± 10.6 | 166.5 ± 28.1 |
| Change from BL at 24h | 4.8 ± 5.5 | 12.5 ± 10.6 | 5.3 ± 2.2 | 5.3 ± 6.4 | 9.5 ± 14.0 | 19.5 ± 4.0 | 8.3 ± 21.0 | 25.0 ± 12.7 | 12.5 ± 12.0 | 5.8 ± 10.7 |
| Change from BL at FU | 5.0 ± 20.4 | 26.3 ± 27.2 | 25.3 ± 5.1 | 21.5 ± 15.5 | 28.3 ± 17.7 | 24.3 ± 16.7 | -13.8 ± 33.7 | 6.8 ± 5.4 | -2.5 ± 41.7 | 8.3 ± 9.3 |
Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| mg/dL | Group I Placebo | Group II Placebo | SAD Group I 10mg | SAD Group II 30mg | SAD Group I 100mg | SAD Group II 300mg | SAD Group I 800mg | SAD Group II 2000mg | Group I Placebo + Food | Group I 100mg + Food |
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 50.0 ± 11.1 | 49.8 ± 8.4 | 45.5 ± 11.0 | 49.5 ± 8.9 | 40.0 ± 4.1 | 54.5 ± 5.5 | 51.5 ± 9.6 | 48.0 ± 13.3 | 47.0 ± 17.0 | 45.8 ± 7.3 |
| Change from BL at 24h | -2.8 ± 2.4 | 0.5 ± 3.1 | 1.0 ± 1.2 | -2.5 ± 2.9 | -1.3 ± 2.1 | 2.8 ± 2.2 | -3.0 ± 6.0 | 10.0 ± 7.3 | 2.5 ± 7.8 | -0.3 ± 1.5 |
| Change from BL at FU | 1.8 ± 5.2 | 4.5 ± 5.0 | 6.3 ± 4.6 | 3.0 ± 3.6 | 7.3 ± 2.6 | 2.8 ± 5.1 | -3.0 ± 9.9 | 8.8 ± 7.4 | -2.0 ± 7.1 | 1.5 ± 6.1 |
Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| mg/dL | Group I Placebo | Group II Placebo | SAD Group I 10mg | SAD Group II 30mg | SAD Group I 100mg | SAD Group II 300mg | SAD Group I 800mg | SAD Group II 2000mg | Group I Placebo + Food | Group I 100mg + Food |
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 72.8 ± 19.0 | 88.5 ± 62.1 | 57.3 ± 13.0 | 84.5 ± 46.8 | 72.0 ± 9.6 | 71.0 ± 33.6 | 76.3 ± 15.7 | 117.0 ± 99.5 | 92.5 ± 57.3 | 86.3 ± 20.8 |
| Change from BL at 24h | 16.7 ± 7.2 | 19.0 ± 17.3 | 10.3 ± 3.0 | 31.0 ± 18.1 | 20.3 ± 16.3 | 22.5 ± 18.4 | 27.0 ± 9.5 | -10.3 ± 46.7 | 1.5 ± 29.0 | 7.8 ± 20.2 |
| Change from BL at FU | 16.5 ± 24.5 | 24.5 ± 58.6 | 30.8 ± 48.8 | 47.3 ± 75.3 | 12.5 ± 19.3 | 37.5 ± 86.5 | 37.8 ± 47.1 | -16.5 ± 48.6 | 43.5 ± 89.8 | -1.8 ± 18.6 |
Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| mg/dL | Group I Placebo | Group II Placebo | SAD Group I 10mg | SAD Group II 30mg | SAD Group I 100mg | SAD Group II 300mg | SAD Group I 800mg | SAD Group II 2000mg | Group I Placebo + Food | Group I 100mg + Food |
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 111.1 ± 41.9 | 83.5 ± 24.9 | 88.9 ± 32.5 | 82.5 ± 35.3 | 92.3 ± 46.4 | 98.7 ± 35.6 | 145.9 ± 45.7 | 103.1 ± 40.0 | 134.5 ± 16.3 | 103.5 ± 25.7 |
| Change from BL at 24h | 4.5 ± 6.9 | 8.3 ± 4.6 | 2.9 ± 3.1 | 1.4 ± 6.4 | 6.4 ± 10.3 | 12.8 ± 2.6 | 5.7 ± 16.2 | 16.7 ± 7.8 | 10.0 ± 9.9 | 4.4 ± 7.1 |
| Change from BL at FU | 0.3 ± 19.7 | 17.0 ± 15.6 | 13.3 ± 10.8 | 9.6 ± 6.9 | 18.5 ± 16.4 | 14.2 ± 6.2 | -17.9 ± 35.8 | 1.3 ± 7.7 | -8.5 ± 30.4 | 7.2 ± 6.8 |
Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| mmol/L | Group I Placebo | Group II Placebo | SAD Group I 10mg | SAD Group II 30mg | SAD Group I 100mg | SAD Group II 300mg | SAD Group I 800mg | SAD Group II 2000mg | Group I Placebo + Food | Group I 100mg + Food |
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 25.68 ± 1.38 | 25.22 ± 0.51 | 24.78 ± 1.09 | 25.85 ± 0.53 | 24.85 ± 1.21 | 24.28 ± 0.33 | 27.05 ± 0.91 | 26.03 ± 1.80 | 24.90 ± 0.71 | 25.93 ± 0.84 |
| Change from BL at 24h | -0.05 ± 1.15 | 0.28 ± 1.31 | 1.05 ± 1.27 | 1.18 ± 0.90 | 0.40 ± 0.94 | 2.35 ± 0.70 | -0.17 ± 0.94 | 0.05 ± 1.55 | 1.95 ± 0.64 | 0.05 ± 0.39 |
| Change from BL at FU | -1.22 ± 1.38 | 0.97 ± 1.04 | -0.58 ± 1.46 | 0.95 ± 0.88 | -0.15 ± 0.55 | 1.65 ± 1.20 | -2.38 ± 1.64 | -0.20 ± 1.03 | -0.55 ± 0.49 | -1.23 ± 0.30 |
Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| mU/L | Group I Placebo | Group II Placebo | SAD Group I 10mg | SAD Group II 30mg | SAD Group I 100mg | SAD Group II 300mg | SAD Group I 800mg | SAD Group II 2000mg | Group I Placebo + Food | Group I 100mg + Food |
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 1.45 ± 0.56 | 1.26 ± 0.64 | 1.14 ± 0.36 | 1.14 ± 0.55 | 1.50 ± 0.97 | 1.55 ± 0.66 | 1.83 ± 0.78 | 1.59 ± 1.03 | 2.57 ± 2.31 | 1.93 ± 0.95 |
| Change from BL at 24h | -0.20 ± 0.09 | 0.04 ± 0.29 | -0.12 ± 0.22 | -0.03 ± 0.18 | 0.07 ± 0.22 | 0.46 ± 0.52 | 0.05 ± 0.35 | -0.12 ± 0.25 | -0.54 ± 0.65 | -0.42 ± 0.42 |
| Change from BL at FU | 0.08 ± 0.35 | 0.45 ± 1.02 | 0.10 ± 0.22 | 0.77 ± 0.92 | 0.32 ± 0.27 | 0.11 ± 0.58 | 0.17 ± 0.42 | -0.06 ± 0.21 | -0.69 ± 0.73 | -0.10 ± 0.22 |
Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| ng/dL | Group I Placebo | Group II Placebo | SAD Group I 10mg | SAD Group II 30mg | SAD Group I 100mg | SAD Group II 300mg | SAD Group I 800mg | SAD Group II 2000mg | Group I Placebo + Food | Group I 100mg + Food |
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 1.27 ± 0.14 | 1.22 ± 0.16 | 1.30 ± 0.14 | 1.38 ± 0.17 | 1.25 ± 0.10 | 1.08 ± 0.05 | 1.20 ± 0.14 | 1.15 ± 0.06 | 1.35 ± 0.07 | 1.22 ± 0.17 |
| Change from BL at 24h | -0.05 ± 0.08 | 0.03 ± 0.05 | -0.08 ± 0.10 | -0.08 ± 0.10 | -0.05 ± 0.06 | 0.12 ± 0.05 | 0.05 ± 0.13 | 0.10 ± 0.08 | 0.05 ± 0.07 | 0.03 ± 0.13 |
| Change from BL at FU | 0.03 ± 0.10 | 0.15 ± 0.10 | 0.02 ± 0.22 | 0.05 ± 0.06 | 0.07 ± 0.05 | 0.22 ± 0.05 | 0.05 ± 0.10 | 0.13 ± 0.05 | -0.10 ± 0.14 | 0.10 ± 0.08 |
Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| mg/dL | Group I Placebo | Group II Placebo | SAD Group I 10mg | SAD Group II 30mg | SAD Group I 100mg | SAD Group II 300mg | SAD Group I 800mg | SAD Group II 2000mg | Group I Placebo + Food | Group I 100mg + Food |
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 7.98 ± 2.47 | 7.28 ± 1.86 | 8.65 ± 3.20 | 8.23 ± 2.04 | 8.10 ± 2.93 | 9.03 ± 2.08 | 7.53 ± 0.97 | 8.58 ± 2.68 | 9.85 ± 1.34 | 8.33 ± 1.50 |
| Change from BL at 24h | -0.80 ± 1.83 | 1.40 ± 2.82 | -2.08 ± 2.41 | 2.10 ± 3.81 | -0.50 ± 1.67 | 0.88 ± 3.62 | 0.78 ± 1.75 | 3.25 ± 1.54 | -1.05 ± 0.07 | 0.40 ± 2.22 |
| Change from BL at FU | 1.05 ± 4.59 | 3.80 ± 3.12 | 2.25 ± 5.84 | 3.45 ± 3.45 | 1.93 ± 6.23 | 0.70 ± 2.45 | -0.02 ± 3.40 | 4.33 ± 3.08 | -0.15 ± 0.64 | 1.70 ± 4.59 |
Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| g/L | MAD Group III | MAD Group IV | MAD Group V | Placebo |
|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 65.3 ± 3.8 | 67.3 ± 4.6 | 63.8 ± 1.3 | 66.0 ± 2.1 |
| Change from BL at Day 3 | 4.0 ± 2.4 | 2.3 ± 1.7 | 2.5 ± 1.7 | 1.7 ± 2.3 |
| Change from BL at Day 8 | 7.0 ± 2.9 | 4.3 ± 4.3 | 6.0 ± 4.1 | 4.8 ± 1.7 |
| Change from BL at FU | 5.0 ± 3.4 | 4.8 ± 4.1 | 4.0 ± 2.9 | 1.8 ± 2.0 |
Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| U/L | MAD Group III | MAD Group IV | MAD Group V | Placebo |
|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 66.0 ± 16.1 | 67.3 ± 10.7 | 55.3 ± 7.3 | 52.3 ± 9.5 |
| Change from BL at Day 3 | 7.3 ± 6.7 | 2.0 ± 1.4 | 1.5 ± 3.9 | 1.8 ± 1.8 |
| Change from BL at Day 8 | 13.0 ± 9.7 | 5.0 ± 4.2 | 6.0 ± 6.4 | 3.3 ± 1.9 |
| Change from BL at FU | 9.0 ± 13.3 | 10.8 ± 4.6 | 9.8 ± 5.2 | 3.3 ± 4.0 |
Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| U/L | MAD Group III | MAD Group IV | MAD Group V | Placebo |
|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 20.3 ± 3.8 | 21.5 ± 5.7 | 18.5 ± 0.6 | 23.0 ± 6.6 |
| Change from BL at Day 3 | -2.0 ± 4.2 | -5.0 ± 1.4 | -2.5 ± 1.3 | -1.7 ± 3.6 |
| Change from BL at Day 8 | -1.0 ± 6.1 | -2.8 ± 1.9 | -0.3 ± 2.8 | -1.5 ± 4.8 |
| Change from BL at FU | 1.5 ± 3.9 | 1.3 ± 4.6 | 9.8 ± 16.3 | 2.8 ± 8.2 |
Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| U/L | MAD Group III | MAD Group IV | MAD Group V | Placebo |
|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 129.5 ± 62.0 | 192.3 ± 149.4 | 146.5 ± 70.8 | 229.8 ± 156.0 |
| Change from BL at Day 3 | -48.5 ± 40.7 | -68.8 ± 57.3 | -58.0 ± 53.3 | -106.5 ± 115.2 |
| Change from BL at Day 8 | -50.8 ± 49.4 | -83.8 ± 91.7 | -68.0 ± 57.7 | -123.5 ± 144.9 |
| Change from BL at FU | 27.0 ± 23.1 | -7.5 ± 81.2 | 150.5 ± 313.3 | 42.2 ± 153.5 |
Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| U/L | MAD Group III | MAD Group IV | MAD Group V | Placebo |
|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 15.5 ± 7.0 | 18.3 ± 9.2 | 20.5 ± 14.5 | 21.5 ± 11.3 |
| Change from BL at Day 3 | 0.5 ± 1.0 | 0.3 ± 1.3 | 2.0 ± 2.2 | 0.7 ± 1.2 |
| Change from BL at Day 8 | 0.8 ± 1.9 | 0.3 ± 3.0 | 1.8 ± 2.8 | 0.0 ± 2.2 |
| Change from BL at FU | 1.3 ± 1.3 | -0.5 ± 3.1 | 1.8 ± 2.2 | -0.8 ± 2.5 |
Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| mg/dL | MAD Group III | MAD Group IV | MAD Group V | Placebo |
|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 0.50 ± 0.47 | 0.55 ± 0.13 | 0.63 ± 0.15 | 0.65 ± 0.29 |
| Change from BL at Day 3 | 0.38 ± 0.22 | 0.05 ± 0.13 | 0.20 ± 0.16 | 0.13 ± 0.08 |
| Change from BL at Day 8 | 0.33 ± 0.26 | 0.03 ± 0.21 | 0.18 ± 0.25 | 0.08 ± 0.08 |
| Change from BL at FU | -0.02 ± 0.32 | -0.08 ± 0.21 | 0.08 ± 0.22 | -0.05 ± 0.19 |
Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| mg/dL | MAD Group III | MAD Group IV | MAD Group V | Placebo |
|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 24.8 ± 3.9 | 28.0 ± 5.5 | 29.8 ± 5.1 | 30.2 ± 3.5 |
| Change from BL at Day 3 | 6.0 ± 2.2 | 2.8 ± 2.4 | 2.0 ± 2.6 | 2.5 ± 3.0 |
| Change from BL at Day 8 | 5.8 ± 6.9 | -0.5 ± 3.1 | 0.5 ± 1.3 | -1.0 ± 4.5 |
| Change from BL at FU | 2.3 ± 8.4 | -0.5 ± 6.8 | -0.5 ± 7.1 | -0.3 ± 6.7 |
Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| mg/dL | MAD Group III | MAD Group IV | MAD Group V | Placebo |
|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 0.910 ± 0.042 | 0.960 ± 0.079 | 0.913 ± 0.067 | 0.897 ± 0.110 |
| Change from BL at Day 3 | 0.095 ± 0.025 | 0.122 ± 0.033 | 0.165 ± 0.031 | 0.057 ± 0.050 |
| Change from BL at Day 8 | 0.005 ± 0.247 | 0.122 ± 0.069 | 0.133 ± 0.082 | 0.053 ± 0.056 |
| Change from BL at FU | 0.008 ± 0.130 | -0.020 ± 0.024 | 0.017 ± 0.043 | 0.007 ± 0.039 |
Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| mmol/L | MAD Group III | MAD Group IV | MAD Group V | Placebo |
|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 143.8 ± 1.0 | 141.3 ± 0.5 | 141.0 ± 1.4 | 142.0 ± 0.9 |
| Change from BL at Day 3 | -0.5 ± 0.6 | -1.5 ± 0.6 | 0.8 ± 0.5 | -1.0 ± 0.6 |
| Change from BL at Day 8 | -3.0 ± 0.8 | 0.8 ± 0.5 | 1.0 ± 0.8 | -0.5 ± 1.4 |
| Change from BL at FU | -1.5 ± 1.0 | -0.3 ± 2.2 | 2.0 ± 2.2 | 0.2 ± 2.1 |
Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| mmol/L | MAD Group III | MAD Group IV | MAD Group V | Placebo |
|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 4.20 ± 0.08 | 4.35 ± 0.19 | 4.40 ± 0.40 | 4.32 ± 0.17 |
| Change from BL at Day 3 | 0.45 ± 0.19 | 0.33 ± 0.37 | 0.10 ± 0.29 | 0.52 ± 0.49 |
| Change from BL at Day 8 | 0.07 ± 0.30 | 0.15 ± 0.39 | 0.25 ± 0.42 | 0.15 ± 0.41 |
| Change from BL at FU | 0.25 ± 0.39 | 0.45 ± 0.31 | 0.25 ± 0.59 | 0.30 ± 0.26 |
Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| mmol/L | MAD Group III | MAD Group IV | MAD Group V | Placebo |
|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 103.8 ± 2.2 | 101.5 ± 0.6 | 102.0 ± 1.8 | 102.2 ± 1.5 |
| Change from BL at Day 3 | -2.5 ± 0.6 | -2.0 ± 1.8 | -1.5 ± 0.6 | -1.5 ± 0.8 |
| Change from BL at Day 8 | -3.5 ± 1.0 | -2.0 ± 1.4 | -2.8 ± 1.0 | -2.2 ± 2.1 |
| Change from BL at FU | -2.0 ± 0.0 | -2.3 ± 1.9 | -2.0 ± 0.8 | -1.3 ± 1.5 |
Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| mmol/L | MAD Group III | MAD Group IV | MAD Group V | Placebo |
|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 2.278 ± 0.117 | 2.310 ± 0.058 | 2.265 ± 0.024 | 2.323 ± 0.039 |
| Change from BL at Day 3 | 0.105 ± 0.051 | 0.083 ± 0.067 | 0.048 ± 0.068 | 0.068 ± 0.046 |
| Change from BL at Day 8 | 0.127 ± 0.091 | 0.083 ± 0.063 | 0.100 ± 0.095 | 0.088 ± 0.037 |
| Change from BL at FU | 0.087 ± 0.088 | 0.083 ± 0.075 | 0.045 ± 0.082 | 0.055 ± 0.037 |
Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| mg/dL | MAD Group III | MAD Group IV | MAD Group V | Placebo |
|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 5.65 ± 1.67 | 4.93 ± 0.91 | 5.40 ± 0.80 | 5.25 ± 1.14 |
| Change from BL at Day 3 | 0.50 ± 0.56 | 0.58 ± 0.39 | 0.75 ± 0.62 | -0.07 ± 0.31 |
| Change from BL at Day 8 | 0.28 ± 1.14 | -0.02 ± 0.43 | 0.15 ± 0.58 | -0.63 ± 0.52 |
| Change from BL at FU | 0.08 ± 0.92 | 0.55 ± 0.52 | 0.22 ± 0.81 | -0.05 ± 0.42 |
Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| U/L | MAD Group III | MAD Group IV | MAD Group V | Placebo |
|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 26.5 ± 6.1 | 26.5 ± 3.3 | 32.8 ± 12.1 | 34.2 ± 10.3 |
| Change from BL at Day 3 | -1.8 ± 3.1 | 0.0 ± 1.8 | 26.0 ± 55.4 | 1.2 ± 4.4 |
| Change from BL at Day 8 | -0.3 ± 4.1 | 1.3 ± 7.4 | 50.5 ± 106.4 | 1.0 ± 5.1 |
| Change from BL at FU | 3.5 ± 3.3 | 17.3 ± 24.4 | -2.8 ± 7.4 | -1.8 ± 7.6 |
Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| U/L | MAD Group III | MAD Group IV | MAD Group V | Placebo |
|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 25.3 ± 9.7 | 21.3 ± 17.4 | 20.5 ± 6.8 | 22.3 ± 5.2 |
| Change from BL at Day 3 | 0.0 ± 5.9 | -0.3 ± 2.2 | -1.3 ± 0.5 | 2.0 ± 4.2 |
| Change from BL at Day 8 | -1.8 ± 12.9 | 2.3 ± 2.6 | 0.3 ± 5.4 | 2.8 ± 5.9 |
| Change from BL at FU | 1.3 ± 11.4 | 6.3 ± 8.3 | 4.8 ± 7.9 | 2.3 ± 6.9 |
Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| mmol/L | MAD Group III | MAD Group IV | MAD Group V | Placebo |
|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 0.978 ± 0.094 | 1.033 ± 0.164 | 0.920 ± 0.121 | 1.000 ± 0.162 |
| Change from BL at Day 3 | 0.102 ± 0.033 | 0.003 ± 0.074 | 0.015 ± 0.073 | -0.005 ± 0.111 |
| Change from BL at Day 8 | 0.052 ± 0.116 | 0.000 ± 0.085 | -0.020 ± 0.068 | -0.002 ± 0.113 |
| Change from BL at FU | -0.030 ± 0.131 | -0.010 ± 0.034 | 0.053 ± 0.189 | -0.002 ± 0.190 |
Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| g/L | MAD Group III | MAD Group IV | MAD Group V | Placebo |
|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 43.3 ± 2.2 | 45.5 ± 3.1 | 42.8 ± 0.5 | 44.7 ± 1.5 |
| Change from BL at Day 3 | 3.3 ± 2.2 | 3.8 ± 1.3 | 1.3 ± 1.0 | 1.5 ± 2.1 |
| Change from BL at Day 8 | 5.3 ± 2.6 | 3.5 ± 3.0 | 4.0 ± 1.8 | 3.8 ± 1.8 |
| Change from BL at FU | 2.8 ± 2.1 | 3.0 ± 2.4 | 3.3 ± 2.1 | 1.7 ± 1.4 |
Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| mg/dL | MAD Group III | MAD Group IV | MAD Group V | Placebo |
|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 89.0 ± 5.4 | 85.5 ± 13.8 | 89.8 ± 7.5 | 87.2 ± 10.0 |
| Change from BL at Day 3 | -6.8 ± 4.5 | 2.8 ± 6.3 | -6.8 ± 7.9 | 1.5 ± 2.5 |
| Change from BL at Day 8 | -6.5 ± 7.0 | -9.5 ± 5.5 | -7.0 ± 6.1 | -3.5 ± 7.7 |
| Change from BL at FU | -2.2 ± 1.4 | 2.0 ± 5.7 | -10.8 ± 7.8 | 0.0 ± 7.2 |
Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| mg/dL | MAD Group III | MAD Group IV | MAD Group V | Placebo |
|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 192.8 ± 33.5 | 191.0 ± 11.3 | 203.5 ± 7.4 | 177.8 ± 30.7 |
| Change from BL at Day 3 | 20.0 ± 11.5 | 8.8 ± 9.7 | 13.5 ± 4.0 | 19.7 ± 15.3 |
| Change from BL at Day 8 | 32.3 ± 25.3 | 2.5 ± 20.5 | 13.3 ± 17.7 | 24.3 ± 24.4 |
| Change from BL at FU | 9.3 ± 14.2 | 8.0 ± 22.2 | 9.8 ± 17.8 | -5.5 ± 8.6 |
Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| mg/dL | MAD Group III | MAD Group IV | MAD Group V | Placebo |
|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 140.3 ± 77.7 | 83.5 ± 26.3 | 114.0 ± 74.6 | 90.2 ± 67.5 |
| Change from BL at Day 3 | 14.8 ± 32.2 | 35.5 ± 32.7 | 30.5 ± 30.0 | 14.8 ± 29.3 |
| Change from BL at Day 8 | 17.8 ± 44.2 | 46.8 ± 26.9 | 69.0 ± 42.1 | 28.3 ± 18.2 |
| Change from BL at FU | 16.0 ± 52.1 | 0.5 ± 33.5 | 20.3 ± 56.6 | -8.0 ± 39.0 |
Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| mg/dL | MAD Group III | MAD Group IV | MAD Group V | Placebo |
|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 114.1 ± 32.7 | 112.9 ± 19.0 | 127.0 ± 18.1 | 93.3 ± 23.7 |
| Change from BL at Day 3 | 17.9 ± 14.5 | 4.9 ± 5.2 | 9.0 ± 7.9 | 18.8 ± 13.6 |
| Change from BL at Day 8 | 33.2 ± 32.8 | 1.4 ± 13.8 | 3.5 ± 20.0 | 25.6 ± 25.7 |
| Change from BL at FU | 8.1 ± 11.0 | 6.9 ± 9.6 | -1.5 ± 20.7 | -1.9 ± 9.7 |
Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| mg/dL | MAD Group III | MAD Group IV | MAD Group V | Placebo |
|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 51.0 ± 15.1 | 61.0 ± 20.1 | 53.5 ± 20.5 | 66.8 ± 17.7 |
| Change from BL at Day 3 | -1.0 ± 5.7 | -3.0 ± 4.8 | -1.5 ± 5.8 | -2.5 ± 6.2 |
| Change from BL at Day 8 | -5.0 ± 6.1 | -7.8 ± 8.6 | -3.5 ± 11.2 | -7.0 ± 6.6 |
| Change from BL at FU | -2.5 ± 2.1 | 1.3 ± 9.9 | 7.5 ± 12.1 | -2.2 ± 8.9 |
Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| mU/L | MAD Group III | MAD Group IV | MAD Group V | Placebo |
|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 1.41 ± 0.78 | 1.48 ± 0.45 | 1.20 ± 0.36 | 1.58 ± 0.41 |
| Change from BL at Day 3 | 0.11 ± 0.33 | 0.09 ± 0.21 | 0.48 ± 0.54 | 0.25 ± 0.39 |
| Change from BL at Day 8 | 0.28 ± 0.35 | 0.45 ± 0.23 | 0.75 ± 0.52 | 0.85 ± 0.54 |
| Change from BL at FU | 0.16 ± 0.50 | -0.15 ± 0.29 | 0.05 ± 0.48 | 0.05 ± 0.39 |
Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| pg/mL | MAD Group III | MAD Group IV | MAD Group V | Placebo |
|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 3.35 ± 0.58 | 3.35 ± 0.26 | 3.30 ± 0.14 | 3.08 ± 0.35 |
| Change from BL at Day 3 | -0.05 ± 0.19 | -0.28 ± 0.29 | -0.15 ± 0.19 | -0.15 ± 0.34 |
| Change from BL at Day 8 | -0.32 ± 0.30 | 0.10 ± 0.27 | -0.13 ± 0.22 | -0.05 ± 0.33 |
| Change from BL at FU | 0.30 ± 0.26 | -0.05 ± 0.30 | 0.18 ± 0.29 | 0.18 ± 0.08 |
Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| ng/dL | MAD Group III | MAD Group IV | MAD Group V | Placebo |
|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 1.20 ± 0.08 | 1.25 ± 0.06 | 1.20 ± 0.18 | 1.07 ± 0.14 |
| Change from BL at Day 3 | 0.05 ± 0.06 | 0.02 ± 0.05 | 0.05 ± 0.06 | 0.03 ± 0.08 |
| Change from BL at Day 8 | 0.12 ± 0.05 | 0.07 ± 0.10 | 0.23 ± 0.10 | 0.17 ± 0.10 |
| Change from BL at FU | 0.12 ± 0.05 | 0.03 ± 0.10 | 0.12 ± 0.05 | 0.10 ± 0.06 |
Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| mmol/L | MAD Group III | MAD Group IV | MAD Group V | Placebo |
|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 27.53 ± 0.54 | 25.53 ± 0.92 | 28.53 ± 0.59 | 27.23 ± 0.87 |
| Change from BL at Day 3 | -0.38 ± 0.79 | 2.20 ± 1.51 | 0.10 ± 1.55 | 0.03 ± 1.40 |
| Change from BL at Day 8 | -1.10 ± 1.62 | 1.42 ± 1.59 | -0.55 ± 1.72 | 0.47 ± 1.69 |
| Change from BL at FU | -1.18 ± 0.69 | 1.68 ± 1.27 | -0.32 ± 1.78 | -0.27 ± 1.87 |
Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.
| mg/dL | MAD Group III | MAD Group IV | MAD Group V | Placebo |
|---|---|---|---|---|
| Baseline (pre-dose Day 1) | 8.63 ± 4.26 | 7.00 ± 1.82 | 7.23 ± 1.08 | 9.12 ± 1.94 |
| Change from BL at Day 3 | 0.98 ± 1.06 | 2.23 ± 4.01 | 1.18 ± 1.41 | 5.93 ± 6.62 |
| Change from BL at Day 8 | 3.13 ± 3.00 | 2.30 ± 2.08 | 1.83 ± 1.56 | 1.23 ± 3.66 |
| Change from BL at FU | 2.75 ± 3.30 | 1.08 ± 1.49 | 6.63 ± 4.95 | -0.12 ± 4.07 |
Change from Day 1 to Day 7 in di-docosahexaenoyl (22:6)-bis(monoacylglycerol) phosphate (di-22:6-BMP) and normalized di-22:6-BMP (urine) - MAD
| ng/mL | MAD Group III | MAD Group IV | MAD Group V | Placebo |
|---|---|---|---|---|
| di-22:6-BMP: Change from Day 1 to Day 7 | -1.473 ± 4.520 | -3.465 ± 4.870 | -2.630 ± 2.633 | -1.592 ± 3.283 |
| Normalized di-22:6-BMP: Change from Day 1 to Day 7 | 1.298 ± 0.819 | 0.060 ± 1.152 | 0.337 ± 1.120 | 1.780 ± 1.874 |
The baseline ECG recording consists of a triplicate recording (3 recordings of a least 3 complexes within a 5 minute window) prior to dosing on Day 1. For the evaluation the average of the 3 recordings will be taken as baseline. Other ECG recordings will be singlet (one recording of at least 3 complexes) prior to dosing, or around the expected Cmax on Day 1 or 7 for the multiple- dose part.
| msec | MAD Group III | MAD Group IV | MAD Group V | Placebo |
|---|---|---|---|---|
| Baseline (Pre-dose Day 1) | 391.3 ± 10.8 | 381.0 ± 28.9 | 384.0 ± 11.0 | 385.2 ± 15.4 |
| Change from baseline at 2h - Day 1 | 3.8 ± 10.3 | 12.3 ± 8.8 | 11.8 ± 9.7 | 0.7 ± 6.9 |
| Change from BL at 24h - Day 1 | -1.0 ± 9.8 | 0.3 ± 6.2 | 11.5 ± 19.2 | -5.7 ± 9.7 |
| Baseline (pre-dose Day 7) | 398.3 ± 7.9 | 386.5 ± 26.1 | 402.0 ± 6.6 | 378.8 ± 13.3 |
| Change from pre-dose Day 7 at 1h - Day 7 | -3.8 ± 9.1 | -3.8 ± 7.9 | -10.3 ± 11.1 | -3.5 ± 6.0 |
| Change from pre-dose Day 7 at 2h - Day 7 | -5.0 ± 4.2 | 5.8 ± 15.2 | 2.5 ± 8.7 | 1.0 ± 16.2 |
| Change from pre-dose Day 7 at 4h | -7.8 ± 7.7 | -3.8 ± 6.2 | -6.5 ± 13.9 | -0.5 ± 12.1 |
| Change from pre-dose Day 7 BL at 6h - Day 7 | 5.3 ± 9.8 | 12.5 ± 7.0 | -1.8 ± 8.3 | 5.8 ± 23.5 |
| Change from pre-dose Day 7 at 8h - Day 7 | -7.0 ± 2.8 | -4.5 ± 9.7 | -11.5 ± 7.2 | 3.0 ± 6.9 |
| Change from pre-dose Day 7 at 12h - Day 7 | 4.5 ± 11.4 | 3.0 ± 5.0 | -9.0 ± 8.1 | 6.7 ± 5.7 |
| Change from BL at pre-dose Day 2 | -1.0 ± 9.8 | 0.3 ± 6.2 | 11.5 ± 19.2 | -5.7 ± 9.7 |
| Change from BL at pre-dose Day 3 | 6.0 ± 14.1 | 0.5 ± 9.7 | 20.5 ± 22.3 | -8.5 ± 5.8 |
| Change from BL at pre-dose Day 4 | 6.5 ± 11.5 | 2.0 ± 14.7 | 7.5 ± 17.1 | -10.2 ± 5.0 |
| Change from BL at pre-dose Day 5 | 13.8 ± 14.3 | 10.3 ± 4.3 | 14.0 ± 14.2 | -8.5 ± 5.6 |
| Change from BL at pre-dose Day 6 | 5.5 ± 9.9 | -2.3 ± 6.7 | 13.5 ± 13.8 | -10.5 ± 14.5 |
| Change from BL at pre-dose Day 7 | 7.0 ± 6.5 | 5.5 ± 9.6 | 18.0 ± 9.2 | -11.3 ± 7.7 |
| Change from BL at FU | 7.8 ± 9.7 | 11.0 ± 3.2 | 10.5 ± 24.4 | 3.8 ± 14.3 |
The baseline ECG recording consists of a triplicate recording (3 recordings of a least 3 complexes within a 5 minute window) prior to dosing on Day 1. For the evaluation of the PQ interval the average of the 3 recordings will be taken as baseline.
| msec | MAD Group III | MAD Group IV | MAD Group V | Placebo |
|---|---|---|---|---|
| Baseline (Pre-dose Day 1) | 185.8 ± 33.4 | 160.5 ± 18.5 | 162.0 ± 7.0 | 171.8 ± 20.0 |
| Change from baseline at 2h - Day 1 | 2.8 ± 2.8 | -1.5 ± 3.0 | 6.0 ± 5.0 | 6.2 ± 10.3 |
| Change from BL at 24h - Day 1 | -5.8 ± 6.1 | -0.5 ± 1.9 | 2.0 ± 6.6 | -6.5 ± 14.0 |
| Baseline (pre-dose Day 7) | 191.5 ± 33.4 | 164.0 ± 22.9 | 167.5 ± 5.3 | 178.3 ± 11.8 |
| Change from pre-dose Day 7 at 1h - Day 7 | -1.0 ± 4.8 | 5.5 ± 30 | 6.5 ± 2.5 | -1.7 ± 2.0 |
| Change from pre-dose Day 7 at 2h - Day 7 | -3.5 ± 5.7 | -1.5 ± 3.4 | 4.0 ± 4.3 | -14.7 ± 14.7 |
| Change from pre-dose Day 7 at 4h | -9.0 ± 9.0 | -1.0 ± 3.8 | 0.0 ± 1.6 | -14.3 ± 15.0 |
| Change from pre-dose Day 7 BL at 6h - Day 7 | -13.0 ± 4.8 | -3.5 ± 8.2 | -4.5 ± 2.5 | -6.7 ± 5.2 |
| Change from pre-dose Day 7 at 8h - Day 7 | -10.0 ± 5.9 | 0.0 ± 7.3 | -5.0 ± 2.6 | -11.3 ± 4.1 |
| Change from pre-dose Day 7 at 12h - Day 7 | -24.0 ± 23.6 | -1.5 ± 5.7 | -4.5 ± 4.1 | -4.0 ± 7.6 |
| Change from BL at pre-dose Day 2 | -5.8 ± 6.1 | -0.5 ± 1.9 | 2.0 ± 6.6 | -6.5 ± 14.0 |
| Change from BL at pre-dose Day 3 | 6.3 ± 5.4 | 4.5 ± 2.5 | 0.0 ± 6.8 | -6.8 ± 7.3 |
| Change from BL at pre-dose Day 4 | 6.3 ± 3.3 | 9.5 ± 1.0 | 7.5 ± 6.8 | -3.8 ± 19.7 |
| Change from BL at pre-dose Day 5 | -2.3 ± 7.4 | 4.0 ± 6.2 | 8.5 ± 10.1 | -2.2 ± 16.9 |
| Change from BL at pre-dose Day 6 | -0.3 ± 9.5 | 3.0 ± 4.3 | 6.0 ± 3.5 | 5.2 ± 19.0 |
| Change from BL at pre-dose Day 7 | 5.8 ± 6.8 | 3.5 ± 5.7 | 5.5 ± 5.7 | 6.5 ± 20.9 |
| Change from BL at FU | -6.8 ± 12.0 | -2.5 ± 3.4 | -3.5 ± 6.4 | 0.5 ± 16.2 |
The baseline ECG recording consists of a triplicate recording (3 recordings of a least 3 complexes within a 5 minute window) prior to dosing on Day 1. For the evaluation the average of the 3 recordings will be taken as baseline. Other ECG recordings will be singlet (one recording of at least 3 complexes) prior to dosing, or around the expected Cmax on Day 1 or 7 for the multiple- dose part.
| msec | MAD Group III | MAD Group IV | MAD Group V | Placebo |
|---|---|---|---|---|
| Baseline (Pre-dose Day 1) | 99.3 ± 6.9 | 92.5 ± 6.1 | 85.5 ± 8.3 | 98.5 ± 8.2 |
| Change from BL at 2h - Day 1 | 1.3 ± 1.0 | 2.0 ± 1.4 | 6.0 ± 2.9 | -0.2 ± 1.8 |
| Change from BL at 24h - Day 1 | 0.3 ± 2.1 | 2.5 ± 2.4 | 3.5 ± 2.6 | -0.8 ± 1.3 |
| Baseline (pre-dose Day 7) | 99.5 ± 7.2 | 97.0 ± 5.3 | 87.5 ± 7.2 | 98.7 ± 8.8 |
| Change from BL Day 7 at 1h - Day 7 | 0.5 ± 3.0 | 0.0 ± 2.8 | 5.0 ± 2.0 | -0.3 ± 0.8 |
| Change from BL Day 7 at 2h - Day 7 | 0.5 ± 1.9 | 1.0 ± 1.2 | 5.5 ± 1.9 | 0.7 ± 2.4 |
| Change from BL Day 7 at 4h | 0.0 ± 2.8 | -0.5 ± 1.0 | 2.5 ± 2.5 | 0.7 ± 3.0 |
| Change from BL Day 7 BL at 6h - Day 7 | 0.5 ± 1.9 | -2.5 ± 2.5 | 3.0 ± 2.0 | 0.7 ± 2.4 |
| Change from BL Day 7 at 8h - Day 7 | -3.5 ± 1.9 | -0.5 ± 1.9 | 2.0 ± 1.6 | 0.7 ± 4.8 |
| Change from BL Day 7 at 12h - Day 7 | -1.5 ± 3.0 | -2.0 ± 1.6 | 2.0 ± 0.0 | -2.0 ± 3.6 |
| Change from BL at pre-dose Day 2 | 0.3 ± 2.1 | 2.5 ± 2.4 | 3.5 ± 2.6 | -0.8 ± 1.3 |
| Change from BL at pre-dose Day 3 | 0.3 ± 2.1 | 2.5 ± 1.3 | 2.0 ± 3.7 | -0.8 ± 2.4 |
| Change from BL at pre-dose Day 4 | -0.8 ± 1.5 | 5.0 ± 3.4 | 3.5 ± 1.7 | -0.5 ± 2.7 |
| Change from BL at pre-dose Day 5 | -0.8 ± 1.5 | 2.5 ± 0.6 | 2.5 ± 1.7 | -0.5 ± 2.7 |
| Change from BL at pre-dose Day 6 | -0.3 ± 1.3 | 2.0 ± 2.4 | 1.0 ± 2.2 | -1.8 ± 2.0 |
| Change from BL at pre-dose Day 7 | 0.3 ± 0.5 | 4.5 ± 1.3 | 2.0 ± 1.4 | 0.2 ± 3.1 |
| Change from BL at FU | 0.3 ± 2.6 | 0.5 ± 1.7 | -2.5 ± 2.4 | -1.8 ± 5.2 |
The baseline ECG recording consists of a triplicate recording (3 recordings of a least 3 complexes within a 5 minute window) prior to dosing on Day 1. For the evaluation the average of the 3 recordings will be taken as baseline. Other ECG recordings will be singlet (one recording of at least 3 complexes) prior to dosing, or around the expected Cmax on Day 1 or 7 for the multiple- dose part.
| msec | MAD Group III | MAD Group IV | MAD Group V | Placebo |
|---|---|---|---|---|
| Baseline (Pre-dose Day 1) | 410.5 ± 41.8 | 391.5 ± 8.5 | 399.0 ± 11.2 | 410.2 ± 33.0 |
| Change from BL at 2h - Day 1 | -5.5 ± 10.5 | -7.5 ± 16.0 | -4.0 ± 3.7 | 4.2 ± 10.1 |
| Change from BL at 24h - Day 1 | -10.0 ± 11.9 | 1.0 ± 8.8 | -14.5 ± 4.8 | -4.2 ± 14.6 |
| Baseline (pre-dose Day 7) | 393.0 ± 42.6 | 388.5 ± 20.6 | 402.0 ± 18.8 | 406.0 ± 22.9 |
| Change from pre-dose Day 7 at 1h - Day 7 | 5.0 ± 12.4 | -1.0 ± 7.4 | 0.0 ± 9.1 | 1.0 ± 8.1 |
| Change from pre-dose Day 7 at 2h - Day 7 | 0.0 ± 6.5 | -10.5 ± 15.4 | -7.5 ± 10.0 | -2.3 ± 14.2 |
| Change from pre-dose Day 7 at 4h | -7.0 ± 1.2 | -2.0 ± 7.1 | -4.0 ± 11.9 | 10.7 ± 15.9 |
| Change from pre-dose Day 7 BL at 6h - Day 7 | -15.5 ± 14.2 | -17.0 ± 15.2 | -16.5 ± 10.6 | -14.3 ± 26.8 |
| Change from pre-dose Day 7 at 8h - Day 7 | -18.5 ± 13.7 | -1.0 ± 12.7 | -11.0 ± 11.9 | -3.0 ± 17.9 |
| Change from pre-dose Day 7 at 12h - Day 7 | -20.0 ± 14.1 | -20.0 ± 6.3 | -11.5 ± 9.6 | -8.7 ± 19.9 |
| Change from BL at pre-dose Day 2 | -10.0 ± 11.9 | 1.0 ± 8.8 | -14.5 ± 4.8 | -4.2 ± 14.6 |
| Change from BL at pre-dose Day 3 | -10.5 ± 20.0 | 7.5 ± 6.6 | -10.0 ± 9.6 | -6.2 ± 12.6 |
| Change from BL at pre-dose Day 4 | -6.0 ± 26.1 | -3.5 ± 13.4 | 6.0 ± 4.5 | -0.2 ± 20.7 |
| Change from BL at pre-dose Day 5 | -9.0 ± 24.9 | -13.0 ± 11.9 | 3.0 ± 9.4 | 1.2 ± 16.1 |
| Change from BL at pre-dose Day 6 | -16.0 ± 23.5 | -0.5 ± 12.2 | -4.5 ± 10.1 | -3.8 ± 11.9 |
| Change from BL at pre-dose Day 7 | -17.5 ± 32.3 | -3.0 ± 14.8 | 3.0 ± 9.4 | -4.2 ± 16.1 |
| Change from BL at FU | -22.0 ± 13.2 | -10.5 ± 14.6 | -23.0 ± 14.3 | 13.2 ± 23.9 |
The baseline ECG recording consists of a triplicate recording (3 recordings of a least 3 complexes within a 5 minute window) prior to dosing on Day 1. For the evaluation the average of the 3 recordings will be taken as baseline.
| msec | SAD Group I Placebo | SAD Group II Placebo | SAD Group I 10mg | SAD Group II 30mg | SAD Group I 100mg | SAD Group II 300mg | SAD Group I 800mg | SAD Group II 2000mg | Group I Placebo + Food | Group II 100mg + Food |
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (Pre-dose Day 1) | 195.5 ± 28.9 | 165.0 ± 21.6 | 154.5 ± 39.2 | 159.8 ± 23.0 | 155.0 ± 24.4 | 176.5 ± 21.4 | 171.8 ± 15.9 | 176.0 ± 17.7 | 177.0 ± 26.9 | 147.5 ± 25.2 |
| Change from baseline at 1h | -1.2 ± 4.0 | 3.3 ± 7.4 | -0.5 ± 1.9 | -1.3 ± 5.7 | -4.0 ± 3.7 | 4.0 ± 2.8 | 8.8 ± 3.0 | 20.5 ± 7.5 | -9.0 ± 9.9 | -3.5 ± 4.4 |
| Change from BL at 2h post dose | 1.2 ± 3.9 | -0.7 ± 3.7 | -3.0 ± 3.7 | 1.3 ± 3.8 | -3.0 ± 3.8 | 4.5 ± 5.7 | 8.3 ± 11.8 | 16.0 ± 5.9 | -11.0 ± 9.9 | -1.0 ± 2.6 |
| Change from BL at 4h post dose | -1.5 ± 8.8 | -2.3 ± 0.8 | -2.0 ± 2.6 | 4.8 ± 4.4 | -3.5 ± 5.3 | 0.0 ± 4.0 | 3.3 ± 5.7 | 10.0 ± 6.3 | -5.0 ± 7.1 | -1.5 ± 3.0 |
| Change from BL at 6h post dose | -1.2 ± 3.6 | -2.7 ± 3.3 | -2.0 ± 2.6 | 0.8 ± 7.2 | -7.5 ± 5.3 | -5.5 ± 8.5 | -3.3 ± 8.8 | 9.0 ± 6.0 | -11.0 ± 12.7 | -1.5 ± 1.9 |
| Change from BL at 8h post dose | -3.2 ± 3.6 | 1.0 ± 6.2 | -6.5 ± 5.5 | -1.3 ± 7.4 | -8.0 ± 4.3 | -8.0 ± 8.6 | -5.3 ± 7.8 | 1.0 ± 10.4 | -6.0 ± 2.8 | -4.0 ± 3.7 |
| Change from BLat 12h post dose | -1.8 ± 4.7 | -3.7 ± 8.3 | -4.0 ± 4.8 | -1.8 ± 4.9 | -6.5 ± 4.4 | -9.5 ± 10.6 | -4.3 ± 5.7 | 0.5 ± 7.7 | -9.0 ± 12.7 | -1.5 ± 4.7 |
| Change from BL at 24h post dose | -2.2 ± 3.3 | -3.7 ± 8.5 | -4.5 ± 8.4 | -4.3 ± 2.6 | -7.0 ± 3.5 | -6.5 ± 3.0 | -4.3 ± 4.9 | -5.5 ± 8.9 | 0.0 ± 0.0 | -2.0 ± 2.8 |
| Change from BL at FU | -5.5 ± 4.9 | -1.3 ± 7.4 | -5.0 ± 4.3 | -7.3 ± 2.2 | -11.0 ± 5.3 | -3.0 ± 9.3 | -9.8 ± 4.9 | -7.0 ± 2.6 | -16.0 ± 14.1 | -3.5 ± 5.0 |
The baseline ECG recording consists of a triplicate recording (3 recordings of a least 3 complexes within a 5 minute window) prior to dosing on Day 1. For the evaluation the average of the 3 recordings will be taken as baseline.
| msec | SAD Group I Placebo | SAD Group II Placebo | SAD Group I 10mg | SAD Group II 30mg | SAD Group I 100mg | SAD Group II 300mg | SAD Group I 800mg | SAD Group II 2000mg | Group I Placebo + Food | Group II 100mg + Food |
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (Pre-dose Day 1) | 103.0 ± 8.3 | 97.0 ± 9.6 | 99.3 ± 3.3 | 97.8 ± 7.6 | 106.5 ± 10.2 | 92.5 ± 13.9 | 104.5 ± 10.6 | 94.0 ± 8.8 | 95.0 ± 7.1 | 105.5 ± 8.3 |
| Change from baseline at 1h | -0.7 ± 2.0 | 1.0 ± 5.2 | -1.3 ± 0.5 | 0.3 ± 2.2 | 0.0 ± 2.8 | 3.5 ± 3.4 | 1.5 ± 6.4 | 26.0 ± 6.9 | 1.0 ± 1.4 | 0.0 ± 2.8 |
| Change from BL at 2h post dose | -2.0 ± 3.0 | 0.7 ± 3.2 | -1.3 ± 1.3 | -0.3 ± 1.0 | -2.5 ± 1.0 | 3.0 ± 2.6 | 2.5 ± 7.2 | 20.5 ± 7.7 | 0.0 ± 0.0 | -2.0 ± 2.8 |
| Change from BL at 4h post dose | -1.0 ± 3.0 | -0.7 ± 2.2 | -1.3 ± 1.7 | -0.8 ± 0.5 | -2.0 ± 0.0 | 2.0 ± 2.8 | 2.5 ± 3.0 | 17.0 ± 6.0 | 0.0 ± 2.8 | -3.5 ± 3.4 |
| Change from BL at 6h post dose | 0.3 ± 3.8 | 0.3 ± 1.6 | 0.8 ± 2.6 | -0.3 ± 2.8 | -1.5 ± 1.0 | 3.5 ± 2.5 | 1.5 ± 2.5 | 14.5 ± 5.3 | 1.0 ± 1.4 | -1.5 ± 3.4 |
| Change from BL at 8h post dose | -2.0 ± 2.8 | -1.0 ± 1.3 | 1.3 ± 3.3 | -0.8 ± 2.1 | -2.0 ± 1.6 | 2.5 ± 1.9 | 0.0 ± 6.7 | 13.0 ± 4.8 | 0.0 ± 0.0 | -0.5 ± 1.9 |
| Change from BL at 12h post dose | -0.7 ± 3.6 | -1.7 ± 1.0 | 0.3 ± 2.5 | -0.3 ± 2.5 | -1.5 ± 2.5 | 1.0 ± 2.6 | 2.5 ± 3.0 | 7.0 ± 2.0 | 0.0 ± 0.0 | -2.5 ± 3.0 |
| Change from BL at 24h post dose | -2.7 ± 5.3 | -1.7 ± 3.4 | -1.3 ± 0.5 | -2.3 ± 2.2 | -1.5 ± 1.9 | 1.5 ± 4.4 | 0.0 ± 1.6 | 4.0 ± 0.0 | -3.0 ± 4.2 | -1.0 ± 2.0 |
| Change from BL at FU | -1.3 ± 6.2 | -0.7 ± 4.4 | -1.3 ± 3.5 | 0.8 ± 6.4 | -2.5 ± 4.1 | 0.0 ± 3.3 | -3.0 ± 5.3 | -0.5 ± 2.5 | -1.0 ± 4.2 | -1.5 ± 4.7 |
The baseline ECG recording consists of a triplicate recording (3 recordings of a least 3 complexes within a 5 minute window) prior to dosing on Day 1. For the evaluation the average of the 3 recordings will be taken as baseline.
| msec | SAD Group I Placebo | SAD Group II Placebo | SAD Group I 10mg | SAD Group II 30mg | SAD Group I 100mg | SAD Group II 300mg | SAD Group I 800mg | SAD Group II 2000mg | Group I Placebo + Food | Group II 100mg + Food |
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (Pre-dose Day 1) | 400.0 ± 18.6 | 415.0 ± 23.5 | 393.3 ± 15.4 | 416.0 ± 15.6 | 404.0 ± 11.4 | 409.0 ± 28.2 | 396.3 ± 15.9 | 398.3 ± 17.3 | 373.0 ± 7.1 | 396.0 ± 12.8 |
| Change from baseline at 1h | 9.7 ± 12.7 | -4.3 ± 13.6 | 2.3 ± 6.4 | -8.5 ± 9.5 | 10.5 ± 5.3 | -3.0 ± 7.4 | -5.8 ± 17.6 | 8.8 ± 22.7 | -11.0 ± 1.4 | -15.5 ± 14.3 |
| Change from BL at 2h post dose | 3.0 ± 8.5 | -7.3 ± 16.2 | 4.8 ± 21.4 | 0.5 ± 9.7 | 9.0 ± 10.9 | -2.5 ± 6.6 | 3.3 ± 17.1 | 4.8 ± 21.9 | -2.0 ± 5.7 | 16.0 ± 11.7 |
| Change from BL at 4h post dose | 9.3 ± 7.5 | -3.7 ± 16.9 | 3.3 ± 9.0 | 6.0 ± 7.1 | 7.0 ± 12.9 | -2.0 ± 11.4 | -3.8 ± 16.7 | 1.8 ± 14.6 | 7.0 ± 4.2 | -4.0 ± 8.5 |
| Change from BL at 6h post dose | -6.7 ± 8.8 | -16.0 ± 14.8 | -9.8 ± 8.5 | -19.5 ± 7.4 | -3.5 ± 13.2 | -11.0 ± 6.2 | -19.3 ± 9.2 | -4.8 ± 16.3 | -14.0 ± 5.7 | -13.0 ± 8.4 |
| Change from BL at 8h post dose | -8.7 ± 4.4 | -24.0 ± 9.9 | -6.8 ± 9.1 | -18.5 ± 4.0 | -4.0 ± 16.6 | -16.0 ± 9.8 | -14.8 ± 9.3 | -5.3 ± 7.1 | -17.0 ± 15.6 | -9.0 ± 9.3 |
| Change from BL at 12h post dose | -8.7 ± 3.3 | -24.3 ± 16.3 | -2.8 ± 9.0 | -15.5 ± 11.2 | -6.5 ± 13.0 | -22.5 ± 6.8 | -12.3 ± 7.5 | -13.3 ± 15.9 | -18.0 ± 17.0 | -10.0 ± 15.5 |
| Change from BL at 24h post dose | -6.7 ± 6.1 | -23.0 ± 13.5 | -11.8 ± 3.0 | -15.5 ± 16.5 | -4.5 ± 8.2 | -17.0 ± 14.7 | -10.3 ± 13.3 | 2.3 ± 4.9 | -3.0 ± 18.4 | -7.0 ± 3.8 |
| Change from BL at FU | -12.0 ± 4.3 | -18.3 ± 11.4 | -13.8 ± 6.7 | -12.5 ± 9.8 | -9.0 ± 5.0 | -12.0 ± 13.4 | -8.3 ± 12.4 | -7.8 ± 10.1 | -2.0 ± 25.5 | -1.0 ± 8.9 |
The baseline ECG recording consists of a triplicate recording (3 recordings of a least 3 complexes within a 5 minute window) prior to dosing on Day 1. For the evaluation the average of the 3 recordings will be taken as baseline.
| msec | SAD Group I Placebo | SAD Group II Placebo | SAD Group I 10mg | SAD Group II 30mg | SAD Group I 100mg | SAD Group II 300mg | SAD Group I 800mg | SAD Group II 2000mg | Group I Placebo + Food | Group II 100mg + Food |
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (Pre-dose Day 1) | 379.3 ± 21.0 | 385.5 ± 9.8 | 382.0 ± 21.4 | 390.5 ± 8.9 | 383.8 ± 24.8 | 386.3 ± 8.0 | 382.0 ± 10.9 | 378.5 ± 19.1 | 367.5 ± 24.7 | 382.3 ± 22.0 |
| Change from BL at 1h | 1.7 ± 7.7 | -0.7 ± 10.1 | -1.0 ± 2.8 | -0.3 ± 6.7 | -3.5 ± 5.0 | 1.8 ± 7.3 | 3.0 ± 8.6 | 39.0 ± 19.0 | 12.5 ± 29.0 | 16.0 ± 7.9 |
| Change from BL at 2h post dose | -0.5 ± 12.8 | -2.8 ± 9.3 | -4.0 ± 18.2 | -6.5 ± 7.9 | -10.8 ± 9.6 | 3.0 ± 8.4 | 9.8 ± 8.3 | 41.3 ± 21.7 | 4.5 ± 25.3 | 10.3 ± 4.0 |
| Change from BL at 4h post dose | 5.5 ± 15.2 | -1.5 ± 17.1 | -7.3 ± 3.3 | -8.3 ± 11.9 | -1.5 ± 7.0 | 6.0 ± 17.8 | 6.5 ± 6.2 | 38.5 ± 10.7 | 9.0 ± 28.3 | 1.8 ± 8.2 |
| Change from BL at 6h post dose | 12.7 ± 4.8 | 3.7 ± 8.4 | 11.5 ± 5.8 | 4.0 ± 13.1 | 0.0 ± 14.9 | 14.0 ± 11.0 | 17.8 ± 1.0 | 41.8 ± 13.8 | 20.0 ± 15.6 | 15.5 ± 6.6 |
| Change from BL at 8h post dose | 3.0 ± 12.3 | 1.2 ± 9.3 | -4.8 ± 7.8 | 6.8 ± 14.2 | 8.5 ± 18.7 | 5.5 ± 12.1 | 8.0 ± 7.4 | 37.5 ± 19.3 | 5.0 ± 12.7 | 5.0 ± 6.5 |
| Change from BL at 12h post dose | 7.0 ± 8.3 | 3.8 ± 8.9 | -1.0 ± 2.2 | -2.8 ± 14.0 | 2.8 ± 13.0 | 11.5 ± 13.1 | 17.8 ± 5.2 | 36.0 ± 9.4 | 17.5 ± 2.1 | 9.5 ± 10.3 |
| Change from BL at 24h post dose | 11.7 ± 19.3 | 0.0 ± 8.6 | 0.0 ± 11.3 | 0.8 ± 15.1 | 3.0 ± 7.1 | 1.5 ± 6.5 | 5.3 ± 9.0 | 15.8 ± 4.9 | -0.5 ± 21.9 | -2.5 ± 5.7 |
| Change from BL at FU | 5.3 ± 17.6 | 13.0 ± 15.4 | 4.8 ± 18.8 | 10.8 ± 15.9 | 8.3 ± 19.8 | 13.3 ± 12.7 | -3.5 ± 6.5 | 9.0 ± 14.4 | 9.0 ± 28.3 | 9.8 ± 18.5 |
Plasma concentrations of KH176 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food), 300mg, 800mg, 2000mg b.i.d.
| hours | SAD Group I 10mg | SAD Group II 30mg | SAD Group I 100mg | SAD Group II 300mg | SAD Group I 800mg | SAD Group II 2000mg | Group I 100mg + Food |
|---|---|---|---|---|---|---|---|
| Terminal Elimination Half-life (T1/2) of KH176 Over 24 Hours: SAD | 0 ± 0 | 10.3 ± 14.6 | 9.10 ± 15.2 | 9.64 ± 4.29 | 9.80 ± 19.1 | 11.5 ± 4.73 | 9.09 ± 3.83 |
Plasma concentrations of KH183 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food) , 300mg, 800mg, 2000mg b.i.d.
| hours | SAD Group I 10mg | SAD Group II 30mg | SAD Group I 100mg | SAD Group II 300mg | SAD Group I 800mg | SAD Group II 2000mg | Group I 100mg + Food |
|---|---|---|---|---|---|---|---|
| Terminal Elimination Half-life (T1/2) of KH183: SAD | 16.6 ± 5.86 | 17.8 ± 19.0 | 15.4 ± 8.44 | 14.3 ± 18.9 | 17.2 ± 18.5 | 18.9 ± 18.7 | 14.9 ± 7.86 |
Plasma concentrations of KH176 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food), 300mg, 800mg, 2000mg b.i.d.
| ng/mL | SAD Group I 10mg | SAD Group II 30mg | SAD Group I 100mg | SAD Group II 300mg | SAD Group I 800mg | SAD Group II 2000mg | Group I 100mg + Food |
|---|---|---|---|---|---|---|---|
| Maximum Concentration (Cmax) of KH176: SAD Group | 12.9 ± 21.3 | 56.2 ± 21.0 | 167 ± 27.2 | 766 ± 53.9 | 2170 ± 27.9 | 5990 ± 20.9 | 165 ± 7.40 |
Plasma concentrations of KH183 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food) , 300mg, 800mg, 2000mg b.i.d.
| ng/mL | SAD Group I 10mg | SAD Group II 30mg | SAD Group I 100mg | SAD Group II 300mg | SAD Group I 800mg | SAD Group II 2000mg | Group I 100mg + Food |
|---|---|---|---|---|---|---|---|
| Maximum Concentration (Cmax) of KH183 Over 24 Hours: SAD | 14.2 ± 49.5 | 49.4 ± 9.00 | 168 ± 29.6 | 497 ± 17.6 | 1100 ± 9.58 | 1780 ± 26.3 | 117 ± 20.0 |
Plasma concentrations of KH183 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.: Cmax was obtained directly from the concentration-time data.
| ng/mL | Cmax Dose 100mg | Cmax - Dose 200mg | Cmax - Dose 400mg |
|---|---|---|---|
| Day 1 | 99.4 ± 20.9 | 251 ± 18.0 | 550 ± 14.1 |
| Day 7 | 152 ± 37.5 | 250 ± 10.6 | 450 ± 28.3 |
Plasma concentrations of KH176 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.
| ng/mL | Cmax Dose 100mg | Cmax - Dose 200mg | Cmax - Dose 400mg |
|---|---|---|---|
| Day 1 | 184 ± 57.0 | 313 ± 20.0 | 1330 ± 27.3 |
| Day 7 | 353 ± 19.1 | 748 ± 29.3 | 2100 ± 27.2 |
Plasma concentrations of KH176 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food), 300mg, 800mg, 2000mg b.i.d.
| hours | SAD Group I 10mg | SAD Group II 30mg | SAD Group I 100mg | SAD Group II 300mg | SAD Group I 800mg | SAD Group II 2000mg | Group I 100mg + Food |
|---|---|---|---|---|---|---|---|
| Time to Maximum Concentration (Tmax) of KH176 Over 24 Hours: SAD | 1.03 ± 55.5 | 1.03 ± 55.5 | 0.931 ± 83.4 | 1.10 ± 85.6 | 1.36 ± 20.5 | 0.931 ± 102 | 2.45 ± 23.7 |
Plasma concentrations of KH183 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food), 300mg, 800mg, 2000mg b.i.d.
| ng/mL | SAD Group I 10mg | SAD Group II 30mg | SAD Group I 100mg | SAD Group II 300mg | SAD Group I 800mg | SAD Group II 2000mg | Group I 100mg + Food |
|---|---|---|---|---|---|---|---|
| Time to Reach Peak Plasma Concentration (Tmax) of KH183: SAD | 1.32 ± 34.8 | 1.46 ± 29.1 | 1.32 ± 34.8 | 1.31 ± 34.7 | 1.61 ± 14.5 | 1.57 ± 33.7 | 2.45 ± 23.7 |
Plasma concentrations of KH176 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.
| hours | Tmax Dose 100mg | Tmax - Dose 200mg | Tmax - Dose 400mg |
|---|---|---|---|
| Day 1 | 1.57 ± 173 | 1.73 ± 16.7 | 0.866 ± 70.4 |
| Day 7 | 0.931 ± 48.1 | 1.86 ± 14.5 | 1.36 ± 85.5 |
Plasma concentrations of KH183 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.. tmax was obtained directly from the concentration-time data.
| hours | Tmax Dose 100mg | Tmax - Dose 200mg | Tmax - Dose 400mg |
|---|---|---|---|
| Day 1 | 2.06 ± 116 | 1.57 ± 33.7 | 1.22 ± 23.7 |
| Day 7 | 1.19 ± 36.6 | 1.46 ± 29.1 | 1.61 ± 48.1 |
Plasma concentrations of KH176 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.. Racc was calculated as follows: AUCtau day 7/ AUCtau day 1.
| ratio | Racc Dose 100mg | Racc- Dose 200mg | Racc - Dose 400mg |
|---|---|---|---|
| Accumulation Factor (Racc) of KH176 Over 7 Days: MAD Group | 2.52 ± 31.2 | 2.65 ± 2.5 | 2.17 ± 14.4 |
Plasma concentrations of KH183 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.: Accumulation factor was calculated as follows: AUCtau day 7/ AUCtau day 1.
| ratio | Racc Dose 100mg | Racc- Dose 200mg | Racc - Dose 400mg |
|---|---|---|---|
| Accumulation Factor (Racc) of KH183 (Active Metabolite of KH176): MAD Group | 1.86 ± 46.7 | 1.32 ± 13.1 | 1.19 ± 24.7 |
Plasma concentrations of KH183 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food) , 300mg, 800mg, 2000mg b.i.d.
| h*ng/mL | SAD Group I 10mg | SAD Group II 30mg | SAD Group I 100mg | SAD Group II 300mg | SAD Group I 800mg | SAD Group II 2000mg | Group I 100mg + Food |
|---|---|---|---|---|---|---|---|
| Area Under the Plasma Concentration Versus Time Curve (AUClast) of KH183: SAD Group | 151 ± 26.7 | 547 ± 12.4 | 1810 ± 37.4 | 4830 ± 11.8 | 11700 ± 20.2 | 23900 ± 22.2 | 1590 ± 26.1 |
Plasma concentrations of KH176 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food), 300mg, 800mg, 2000mg b.i.d.
| h*ng/mL | SAD Group I 10mg | SAD Group II 30mg | SAD Group I 100mg | SAD Group II 300mg | SAD Group I 800mg | SAD Group II 2000mg | Group I 100mg + Food |
|---|---|---|---|---|---|---|---|
| Area Under the Plasma Concentration Versus Time Curve (AUClast) of KH176: SAD Group | 75 ± 14.8 | 389 ± 8.16 | 1310 ± 16.7 | 6320 ± 20.2 | 21000 ± 27.5 | 61200 ± 9.07 | 1650 ± 1.67 |
Plasma concentrations of KH176 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.
| h*ng/mL | AUCtau Dose 100mg | AUCtau - Dose 200mg | AUCtau - Dose 400mg |
|---|---|---|---|
| Day 1 | 1090 ± 49.3 | 2250 ± 26.1 | 6890 ± 19.2 |
| Day 7 | 2760 ± 22.6 | 5960 ± 26.8 | 14900 ± 28.2 |
Plasma concentrations of KH183 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.
| h*ng/mL | AUCtau Dose 100mg | AUCtau - Dose 200mg | AUCtau - Dose 400mg |
|---|---|---|---|
| Day 1 | 702 ± 29.2 | 1680 ± 21.0 | 3600 ± 11.1 |
| Day 7 | 1310 ± 29.5 | 2220 ± 12.7 | 4270 ± 30.5 |
Plasma concentrations of KH183 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food) , 300mg, 800mg, 2000mg b.i.d.
| h*ng/mL | SAD Group I 10mg | SAD Group II 30mg | SAD Group I 100mg | SAD Group II 300mg | SAD Group I 800mg | SAD Group II 2000mg | Group I 100mg + Food |
|---|---|---|---|---|---|---|---|
| Area Under the Plasma Concentration-time Curve From Time Zero Until Infinity (AUCl0-inf) of KH183: SAD | 234 ± 26.7 | 881 ± 19.6 | 2690 ± 38.4 | 6690 ± 11.0 | 18700 ± 26.7 | 41300 ± 10.5 | 2410 ± 29.1 |
Plasma concentrations of KH176 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food) , 300mg, 800mg, 2000mg b.i.d.
| h*ng/mL | SAD Group I 10mg | SAD Group II 30mg | SAD Group I 100mg | SAD Group II 300mg | SAD Group I 800mg | SAD Group II 2000mg | Group I 100mg + Food |
|---|---|---|---|---|---|---|---|
| Area Under the Plasma Concentration-time Curve From Time Zero Until Infinity (AUCl0-inf) of KH176: SAD | 0 ± 0 | 474 ± 8.39 | 1540 ± 13.1 | 7500 ± 19.1 | 25800 ± 33.9 | 79100 ± 8.82 | 1970 ± 1.04 |
Urine concentrations of KH176 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food), 300mg, 800mg, 2000mg b.i.d.
| percentage of dose excreted | SAD Group I 10mg | SAD Group II 30mg | SAD Group I 100mg | SAD Group II 300mg | SAD Group I 800mg | SAD Group II 2000mg |
|---|---|---|---|---|---|---|
| KH176: Percentage of Administered Dose Excreted in Urine: SAD | 9.71 ± 37.4 | 10.5 ± 45.6 | 10.4 ± 29.5 | 9.53 ± 65.2 | 10.9 ± 41.6 | 12.4 ± 20.7 |
Urine concentrations of KH176 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food), 300mg, 800mg, 2000mg b.i.d.
| percentage of dose excreted | SAD Group I 10mg | SAD Group II 30mg | SAD Group I 100mg | SAD Group II 300mg | SAD Group I 800mg | SAD Group II 2000mg |
|---|---|---|---|---|---|---|
| KH183: Percentage of Administered Dose Excreted in Urine: SAD | 4.56 ± 53.0 | 6.42 ± 14.5 | 5.18 ± 28.8 | 3.81 ± 82.9 | 3.86 ± 31.0 | 3.33 ± 32.8 |
Urine concentrations of KH176 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food), 300mg, 800mg, 2000mg b.i.d.
| percentage of dose excreted | SAD Group I 10mg | SAD Group II 30mg | SAD Group I 100mg | SAD Group II 300mg | SAD Group I 800mg | SAD Group II 2000mg |
|---|---|---|---|---|---|---|
| KH176 + KH183: Percentage of Administered Dose Excreted in Urine: SAD | 14.4 ± 40.0 | 17.2 ± 28.6 | 15.8 ± 24.5 | 13.4 ± 69.9 | 14.8 ± 38.4 | 15.9 ± 16.4 |
Urine concentrations of KH176 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.
| percentage of dose excreted | MAD Group Dose 100mg | MAD Group - Dose 200mg | MAD Group - Dose 400mg |
|---|---|---|---|
| KH176: Percentage of Administered Dose Excreted in Urine: MAD | 14.9 ± 77.8 | 13.4 ± 36.4 | 14.0 ± 14.5 |
Urine concentrations of KH183 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.
| percentage of dose excreted | MAD Group Dose 100mg | MAD Group - Dose 200mg | MAD Group - Dose 400mg |
|---|---|---|---|
| KH183: Percentage of Administered Dose Excreted in Urine: MAD | 5.30 ± 120.2 | 3.79 ± 39.2 | 4.85 ± 43.8 |
Urine concentrations of KH176 and KH183 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.
| percentage of dose excreted | MAD Group Dose 100mg | MAD Group - Dose 200mg | MAD Group - Dose 400mg |
|---|---|---|---|
| KH173 + KH183: Percentage of Administered Dose Excreted in Urine: MAD | 20.7 ± 79.3 | 17.4 ± 33.3 | 19.0 ± 17.9 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group I Placebo | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Group II Placebo | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| SAD Group I 10mg | 0/4 (0%) | 0/4 (0%) | 2/4 (50%) |
| SAD Group II 30mg | 0/4 (0%) | 0/4 (0%) | 3/4 (75%) |
| SAD Group I 100mg | 0/4 (0%) | 0/4 (0%) | 4/4 (100%) |
| SAD Group II 300mg | 0/4 (0%) | 0/4 (0%) | 1/4 (25%) |
| SAD Group I 800mg | 0/4 (0%) | 0/4 (0%) | 0/4 (0%) |
| SAD Group II 2000mg | 0/4 (0%) | 0/4 (0%) | 4/4 (100%) |
| Group I Placebo + Food | 0/2 (0%) | 0/2 (0%) | 1/2 (50%) |
| Group I 100mg + Food | 0/4 (0%) | 0/4 (0%) | 1/4 (25%) |
| MAD Group III 200mg | 0/4 (0%) | 0/4 (0%) | 3/4 (75%) |
| MAD Group IV 400mg | 0/4 (0%) | 0/4 (0%) | 3/4 (75%) |
| MAD Group V 800mg | 0/4 (0%) | 0/4 (0%) | 4/4 (100%) |
| Placebo | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Event | Group I Placebo | Group II Placebo | SAD Group I 10mg | SAD Group II 30mg | SAD Group I 100mg | SAD Group II 300mg | SAD Group I 800mg | SAD Group II 2000mg | Group I Placebo + Food | Group I 100mg + Food | MAD Group III 200mg | MAD Group IV 400mg | MAD Group V 800mg | Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DizzinessNervous system disorders | 2/6 | 0/6 | 0/4 | 2/4 | 3/4 | 1/4 | 0/4 | 3/4 | 0/2 | 0/4 | 0/4 | 0/4 | 0/4 | 1/6 |
| HeadacheNervous system disorders | 2/6 | 0/6 | 0/4 | 1/4 | 3/4 | 0/4 | 0/4 | 1/4 | 0/2 | 0/4 | 2/4 | 1/4 | 1/4 | 3/6 |
| Paraesthesia oralGastrointestinal disorders | 0/6 | 0/6 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 3/4 | 0/2 | 0/4 | 0/4 | 0/4 | 0/4 | 0/6 |
| Electrocardiogram QT prolongedInvestigations | 0/6 | 0/6 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 3/4 | 0/2 | 0/4 | 0/4 | 0/4 | 1/4 | 0/6 |
| Brundle branch block rightCardiac disorders | 0/6 | 0/6 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 2/4 | 0/2 | 0/4 | 0/4 | 0/4 | 0/4 | 0/6 |
| NauseaGastrointestinal disorders | 1/6 | 0/6 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 2/4 | 0/2 | 0/4 | 0/4 | 0/4 | 1/4 | 2/6 |
| VomitingGastrointestinal disorders | 0/6 | 0/6 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 2/4 | 0/2 | 0/4 | 0/4 | 0/4 | 0/4 | 0/6 |
| Eosinophil count increasedInvestigations | 0/6 | 0/6 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 1/2 | 0/4 | 0/4 | 0/4 | 0/4 | 0/6 |
| Skin irritationSkin and subcutaneous tissue disorders | 0/6 | 0/6 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/2 | 0/4 | 0/4 | 1/4 | 2/4 | 2/6 |
| Lipase increasedInvestigations | 0/6 | 0/6 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/2 | 0/4 | 0/4 | 0/4 | 2/4 | 0/6 |
SAD:14 subjects divided in two groups of 7 subjects were included. Two subjects prematurely withdrew from the study after dosing period 2 for non-medical reasons. MAD part:18 subjects divided in 3 groups of 6 subjects were included. Two subjects prematurely withdrew from the study for non-medical reasons and were replaced.
| Age, Continuous(years) | SAD Group I | SAD Group II | MAD Group III | MAD Group IV | MAD Group V | Placebo | Total |
|---|---|---|---|---|---|---|---|
| Mean | 30.4 ± 10.5 | 32.0 ± 11.3 | 40.8 ± 13.0 | 34.5 ± 11.6 | 44.0 ± 8.2 | 44.7 ± 9.8 | 40.0 ± 4.0 |
| Sex: Female, Male(Participants) | SAD Group I | SAD Group II | MAD Group III | MAD Group IV | MAD Group V | Placebo | Total |
|---|---|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Male | 7 | 7 | 4 | 4 | 4 | 6 | 32 |
| Ethnicity (NIH/OMB)(Participants) | SAD Group I | SAD Group II | MAD Group III | MAD Group IV | MAD Group V | Placebo | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 0 | 1 | 0 | 1 | 3 |
| Not Hispanic or Latino | 6 | 7 | 4 | 3 | 4 | 5 | 29 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | SAD Group I | SAD Group II | MAD Group III | MAD Group IV | MAD Group V | Placebo | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 7 | 7 | 4 | 4 | 4 | 6 | 32 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | SAD Group I | SAD Group II | MAD Group III | MAD Group IV | MAD Group V | Placebo | Total |
|---|---|---|---|---|---|---|---|
| Belgium | 7 | 7 | 4 | 4 | 4 | 6 | 32 |
| Height(cm) | SAD Group I | SAD Group II | MAD Group III | MAD Group IV | MAD Group V | Placebo | Total |
|---|---|---|---|---|---|---|---|
| Mean | 178.07 ± 6.56 | 176.01 ± 8.11 | 184.63 ± 2.81 | 181.75 ± 5.25 | 175.70 ± 3.18 | 175.55 ± 8.25 | 184.0 ± 4.0 |
| Weight(kg) | SAD Group I | SAD Group II | MAD Group III | MAD Group IV | MAD Group V | Placebo | Total |
|---|---|---|---|---|---|---|---|
| Mean | 82.86 ± 10.56 | 74.29 ± 12.61 | 89.05 ± 11.84 | 77.85 ± 11.96 | 81.10 ± 4.82 | 72.03 ± 6.06 | 80.0 ± 8.0 |
| BMI(kg/m^2) | SAD Group I | SAD Group II | MAD Group III | MAD Group IV | MAD Group V | Placebo | Total |
|---|---|---|---|---|---|---|---|
| Mean | 26.09 ± 2.51 | 24.01 ± 4.01 | 26.10 ± 2.74 | 23.60 ± 3.82 | 26.28 ± 1.67 | 23.43 ± 1.98 | 24.0 ± 4.0 |
The record gives a start of May 2015, a primary completion of Sep 2015 and a completion of Oct 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2020, 5 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Trolox
Khondrion BV